2016 ANNUAL REPORT MEMORIAL SLOAN KETTERING CANCER CENTER SLOAN CANCER MEMORIAL KETTERING REPORT ANNUAL 2016

GENERAL INFORMATION 212.639.2000

1275 YORK AVENUE MAKE AN APPOINTMENT NEW YORK, NY 10065 800.525.2225

VISIT US ONLINE WWW.MSKCC.ORG

FACEBOOK.COM/SLOANKETTERING TWITTER.COM/SLOAN_KETTERING YOUTUBE.COM/MSKCC INSTAGRAM.COM/SLOANKETTERING

WWW.MSKCC.ORG/ANNUALREPORT 2016: A YEAR OF I N N O VAT I O N I N N O VAT I O N INNOVATION

Cancer will never have a one-size-fits-all solution. This intricate, challenging, ever- shifting disease is nothing if not complex. And though it’s often described with a single word — cancer — there are actually more than 400 distinct types, each with its own unique characteristics and vulnerabilities.

The doctors, nurses, and scientists at Memorial around the world. We unearthed new answers Sloan Kettering are experts at matching cancer’s to old questions about fundamental biological complexity with an equally nuanced understanding processes. We tested and perfected novel of all its varieties. We strive to choose the optimal technologies and brought them directly to treatment for every patient, and we’re always patients. We led the development of drugs searching for better ways to do so. for cancers that haven’t seen new therapies in decades — and brought them through to FDA We address cancer’s intricacy from every approval. And we opened new locations and possible angle, both by thinking creatively refreshed existing ones to better accommodate and by utilizing the latest, most pioneering the needs of our unique patients. advances in technology, basic and clinical research, treatment, and patient care. In this report, you’ll get to know some of the revolutionary thinkers and caring individuals In 2016, our scientists and clinicians made that make MSK a place like no other. And you’ll field-changing discoveries that will shape the see why 2016 was truly a study in innovation. future of treatment for people with cancer

2. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

CONTENTS MESSAGE FROM THE CHAIRMAN AND THE PRESIDENT 4

INNOVATIONS IN: SCIENCE 8

INNOVATIONS IN: TREATMENT 24

INNOVATIONS IN: CLINICAL RESEARCH 38

INNOVATIONS IN: PATIENT CARE 48

STATISTICAL PROFILE 56

FINANCIAL SUMMARY 58

BOARDS OF OVERSEERS AND MANAGERS 60

LEADERSHIP 61

THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING 63

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING 64

THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER 81

3. INNOVATION

MESSAGE FROM THE CHAIRMAN AND THE PRESIDENT

CRAIG B. THOMPSON DOUGLAS A. WARNER III PRESIDENT AND CHAIR, BOARDS OF OVERSEERS CHIEF EXECUTIVE OFFICER AND MANAGERS

4. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

The nation focused on cancer research and treatment with renewed intensity in 2016 because of a confluence of important developments in the realms of policy and medicine. Vice President Joseph Biden, who lost a son to brain cancer, issued a call to action to scientists, clinicians, and the private sector, urging greater data sharing and collaboration. At the same time, researchers at Memorial Sloan Kettering and other National Cancer Institute–designated cancer centers demonstrated the power of genomics to identify effective treatments that will benefit more people with cancer.

MSK hosted a roundtable conversation with Mr. Biden trials, according to a major study conducted this year that brought together leaders from a variety of areas on behalf of MSK. For example, too many physicians of cancer research and treatment, including our own still believe clinical trials are treatments of last resort. Carol Brown, a gynecologic surgeon and Director of the As a comprehensive cancer center, MSK can play an Office of Diversity Programs in Clinical Care, Research, important role in changing perceptions of clinical trials and Training. Mr. Biden’s Cancer Moonshot initiative and their value in advancing cancer care. helped galvanize Congress to pass the 21st Century Cures Act, which increased funding for the National There are numerous paths to achieving this goal. In Institutes of Health. The legislation enjoyed broad December 2016, we announced a partnership with support among both Republicans and Democrats. Hackensack Meridian Health, one of New Jersey’s largest and most respected healthcare systems. The The Cancer Moonshot initiative highlighted key partnership will enable greater access to clinical trials areas of particular importance: the need for greater for residents of New Jersey, with the goal of accelerating and more diverse participation in clinical research the development of new cures for cancer. At the and the importance of identifying ways to effectively same time, membership in the MSK Cancer Alliance manage the vast amount of data generated by genomic expanded to include the Miami Cancer Institute at sequencing. It also underscored the value of fundamental Baptist Health South Florida. Alliance members, research in the biological sciences in fields as diverse including the Hartford HealthCare Cancer Institute as nanotechnology, epigenetics, and molecular biology. in Connecticut and Lehigh Valley Health Network in These are all areas in which MSK excels. Indeed, the Pennsylvania, are able to offer MSK clinical trials to power of MSK’s collective research accomplishment their patients and participate in key clinical activities was noted last year when the Nature Publishing Group with MSK’s physicians and staff. once again ranked MSK first among all cancer centers in the world for high-quality research output in 2016. MSK continues to focus on how best to analyze the results of cancer DNA sequencing to improve cancer MSK remains committed to increasing patient access treatment and share that information with other health to promising new therapies through clinical trials. systems. MSK physician-scientist Charles Sawyers has Nationwide, members of the public and physicians still taken the lead in addressing this need. A past president harbor many misconceptions about cancer clinical of the American Association for Cancer Research

5. INNOVATION

KATHRYN MARTIN JOSÉ BASELGA JOAN MASSAGUÉ JAMES D. ROBINSON III Chief Operating Physician-in-Chief and Director, Honorary Chair, Officer Chief Medical Officer, Sloan Kettering Boards of Overseers Memorial Hospital Institute and Managers

(AACR), Dr. Sawyers collaborated with the AACR to help researchers unravel how various immune system create an initiative called Project GENIE (Genomics components interact. Evidence Neoplasia Information Exchange) that pulls together data from MSK and seven other leading cancer Our leadership in immunotherapy was further research institutions. The Project GENIE database solidified when we became one of six founding members already includes information on 59 major cancer types, of the Parker Institute for Cancer Immunotherapy with data from nearly 3,000 lung cancer patients, as (PICI), established by tech entrepreneur Sean Parker well as 2,000 patients with breast cancer and more in April 2016. It brings together 300 of the country’s than 2,000 patients with colorectal cancer. This unique leading immunologists, who are dedicated to a single effort enables investigators from around the world to mission: harnessing the power of the immune system ask — and answer — questions about the link between to fight cancer. The first findings from work jointly genes, treatments, and outcomes. conducted through PICI — which is co-directed at MSK by Jedd Wolchok, an expert on melanoma and MSK’s own genetic sequencing efforts hit a significant the immunotherapy approach known as checkpoint milestone in early 2017, when our researchers, led by blockade, and Marcel van den Brink, a specialist in Michael Berger and Ahmet Zehir, reported results blood cancer and bone marrow transplantation — are from the first 10,336 patients who had their tumors beginning to unfold. sequenced through MSK-IMPACT — a test created by our genome scientists, bioinformaticians, and molecular Ongoing investment in MSK’s physical infrastructure pathologists to detect genetic errors in both rare and remains critical to the success of both our scientific and common cancers. Nearly 37 percent of those patients clinical programs. This past year saw the addition of an had a potentially actionable mutation. Since hitting that important new research technology, an advanced cryo- landmark, the test has been used to sequence tumors in electron microscope. Located on the ground floor of the more than 16,000 patients, leading to greater insights Rockefeller Research Laboratories building, the Titan and treatment options for these individuals. Krios further strengthens SKI’s commitment to structural biology and the ability to better understand the structure Immunotherapy represents a substantial opportunity of key biological molecules involved in cancer. to both advance and personalize cancer treatment. Our scientists are generating unprecedented insights in On the clinical side, MSK has reimagined existing this field. In one recent example, Daniel Bachovchin, a space at Memorial Hospital to better meet the needs of chemical biologist in the Sloan Kettering Institute (SKI), neurosurgical and orthopedic patients while developing and colleagues discovered that the immunotherapy new space and programs within the regional care drug Val-boroPro activates the immune system to network. Particularly noteworthy is the December attack cancers through a form of highly inflammatory opening of MSK Monmouth in Middletown, New Jersey. programmed cell death called pyroptosis. This finding, The 120,000-square-foot space will enable us to offer reported in Nature Chemical Biology, unveiled an as-yet- surgical services outside of Manhattan for the first time, unknown element of cell biology, and could offer a tool to along with a comprehensive array of other programs.

6. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

THE COMPLEXITY OF THE HEALTHCARE ENVIRONMENT AND THE ONGOING DEBATE OVER RESEARCH FUNDING DICTATE CONTINUED PRUDENCE — EVEN AS WE DO EVERYTHING POSSIBLE TO ENSURE MSK’S ABILITY TO DRIVE INNOVATION IN CANCER RESEARCH AND TREATMENT.”

The past year saw recruitment of stellar leaders to MSK, MSK’s financial health remains strong, a testament to as well as the promotion of highly talented individuals efforts across the organization to balance programmatic into new roles. Dana Pe’er joined SKI from Columbia growth with overall expense management. The University as Chair of the Computational and Systems complexity of the healthcare environment and the Biology Program; John Petrini, whose research focuses ongoing debate over research funding dictate continued on DNA damage, became Chair of the Molecular Biology prudence — even as we do everything possible to ensure Program. We welcomed Jorge Lopez as MSK’s new MSK’s ability to drive innovation in cancer research General Counsel and recruited Lee Erickson as MSK’s and treatment. first Deputy Physician-in-Chief of Clinical Operations. An outstanding roster of clinical department chairs Philanthropy remains a cornerstone of our success, joined MSK as well: Andrew Kung as Chair of and we would like to recognize the thousands of Pediatrics, Gregory Fischer as Chair of Anesthesiology individuals who support our mission every year. But and Critical Care Medicine, and Jeffrey Drebin as Chair 2016 represented a particularly significant milestone of Surgery. With the successful recruitment of talented in the conclusion of the Campaign for Memorial Sloan and promising junior and mid-career faculty and staff, Kettering. This effort — the most ambitious campaign it’s fair to say we ended the year stronger than we began. in MSK’s history — far surpassed our expectations, with gifts and pledges in excess of $4.2 billion over MSK’s clinicians and scientists also received many 15 years. Thank you to the members of the Boards of individual awards and honors, some recognizing Overseers and Managers and other benefactors for your exceptional achievement over the course of a career leadership. Your support enables the extraordinary and others recognizing future promise. Of note, Peter work being done every day in MSK’s laboratories and Bach, Maria Jasin, and Kenneth Offit were named patient care facilities. With your support, we will strive members of the National Academy of Medicine, to realize even greater progress against cancer in the joining 21 other MSK colleagues. At the same time, years to come. two early-career scientists — Ming Li and Song-Hai Shi — were named Howard Hughes Medical Institute Faculty Scholars.

MSK received another significant honor in 2016, the result of years of hard work and preparation under the leadership of Chief Nursing Officer Elizabeth McCormick DOUGLAS A. WARNER III CRAIG B. THOMPSON and her team: Magnet® designation from the American CHAIR, BOARDS PRESIDENT AND Nurses Credentialing Center. It is the highest and most OF OVERSEERS CHIEF EXECUTIVE OFFICER AND MANAGERS prestigious distinction a healthcare organization can receive for nursing excellence and high-quality patient care. This recognition validated something we have long known: MSK’s nurses are best in class.

7. INNOVATION

INNOVATIONS IN:

8. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

These colorful models of nanoparticles come from the lab of Daniel Heller. Dr. Heller is developing tiny molecules that are capable of delivering drugs directly to the blood vessels that feed tumors.

9. INNOVATION

Like Edison, who lit up our world, and Bell, who transformed how we communicate, MSK scientists cross intellectual borders. They move seamlessly between clinical medicine, basic science, and bioengineering, all with the goal of improving the lives of people with cancer. This past year was no exception.

MSK scientists are some of the best experimentalists around. Whether they’re using new microscopy techniques to probe cell structures or devising molecular machines to detect cancer, each is motivated to ask: What happens if…?

“SOMETIMES, THE REALLY IMPORTANT QUESTIONS TAKE TIME TO SOLVE. BUT WE ARE FULLY CAPABLE OF ANSWERING THEM. WE HAVE THE STABILITY, THE TRACK RECORD, THE TECHNOLOGIES AND FACILITIES, THE BRILLIANT COLLEAGUES. IF MSK IS NOT THE ONE THAT TAKES THE PLUNGE, THEN WHO?”

– JOAN MASSAGUÉ DIRECTOR, SLOAN KETTERING INSTITUTE

10. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

FIRST RESPONDERS: DNA REPAIR

“In order to understand how a machine works, you take it apart,” says John Petrini, Chair of the Molecular Biology Program at the Sloan Kettering JOHN PETRINI Institute. For more than 20 years, Dr. Petrini has focused his attention on one biological machine in particular, an assembly of three large proteins called the Mre11 complex, which cells use to sense and repair DNA damage.

DNA damage sounds bad, and indeed it can be — it’s one of the main causes of cancer. But thanks to the Mre11 complex, this damage is usually caught quickly and mended without incident.

You can think of the Mre11 complex as a kind of emergency first responder. When a chromosome breaks, Mre11 both sounds the alarm to recruit additional emergency personnel and immediately begins steadying the injury. When Mre11 has completed its work, the DNA damage will either be repaired or the cell will die.

Dr. Petrini’s longstanding study of DNA repair machinery is yielding important insights into a fundamental biological process. But there’s more to it than that. His findings are helping clinicians and patients too. “There’s absolutely no question that manipulating the DNA damage response can confer therapeutic advantage,” Dr. Petrini says, noting that cancer cells are more sensitive to drugs that prevent DNA repair. His research illustrates the elegant interplay between biological discovery and clinical application that is at the heart of the MSK model of innovation.

continued

The DNA double helix, as shown here, stores genetic information in the sequence of its bases. DNA damage, a focus of researcher John Petrini, can lead to cancer.

11. INNOVATION

A TWO-WAY STREET CREATIVE DESTRUCTION Several years ago, doctors at Memorial Hospital As molecular biologist Scott Keeney knows, were conducting a clinical trial of an experimental DNA breakage is not just something that occurs drug that interfered with DNA repair. The by accident. In some biological contexts, it’s results were mostly discouraging, and the study necessary — even beneficial. closed. However, in one patient — a woman with advanced bladder cancer — the treatment worked Take the formation of sex cells, sperm and egg. beautifully. She had a complete response and is We learned in high school about the process of still alive more than six years later. recombination, or crossing-over — when the arms of maternal and paternal chromosomes physically To understand what was unique about her tumor, swap segments. This naturally occurring genetic doctors sequenced its genome. What they found shuffling is why no two family members — with the was that this patient had a mutation in the Mre11 exception of identical twins — look exactly alike. complex. Without John Petrini’s 20-plus years of study, the clinicians would not have been able For many years, how cells initiated recombination to home in on this mutation or understand its was mostly a mystery. But then, in the late 1990s, significance. And for Dr. Petrini, the clinical a young postdoctoral fellow at Harvard identified information provided helpful clues about the the mechanism that underlies it: A protein called basic biology of Mre11. It was a perfect synergy Spo11 purposefully made breaks in the DNA of for fueling innovation. The Mre11 genes are now chromosomes. That researcher was Dr. Keeney, included in the hospital’s genetic sequencing and for nearly 20 years he has run his own lab at program, called MSK-IMPACT™, and patients with MSK, studying how double-strand breaks in DNA those mutations can be included in clinical trials. are made and then repaired.

“Every successful therapy, from immunotherapy Dr. Keeney recently reported in Science about a to chemotherapy, is predicated on basic, discovery- surprising discovery his lab made regarding how based science,” Dr. Petrini says. “You almost never broken strands of DNA are “cleaned up” before find your keys just looking under the lamppost.” they are sutured back together, “much like when a wound is repaired in the body,” Dr. Keeney says. They discovered that a protein called Tel1 is necessary to initiate the resection process in yeast, and something similar may happen in humans.

His research sheds light on a fundamental process that also links directly to cancer, since improperly repaired double-strand breaks can lead to mutations. “Clarifying how cells repair double-strand breaks — or fail to do so — is critical to understanding how cancer develops and finding strategies to stop or reverse it,” Dr. Keeney says.

12. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

SCOTT KEENEY

“CLARIFYING HOW CELLS REPAIR DOUBLE-STRAND BREAKS — OR FAIL TO DO SO — IS CRITICAL TO UNDERSTANDING HOW CANCER DEVELOPS.”

– SCOTT KEENEY MOLECULAR BIOLOGIST, SLOAN KETTERING INSTITUTE

13. INNOVATION

LITTLE EARTHQUAKES: NANOTECHNOLOGY DANIEL HELLER

A cell is like a tiny factory. Materials are shipped in and goods are shipped out; old machine parts are recycled and new ones are built. The biological molecules that perform these various functions are the molecular machines that keep the cellular factory humming. The field of nanotechnology is geared toward understanding the rhythms of these various moving parts and the design of nano-size gadgets that can tweak the standard operating procedures.

In Daniel Heller’s lab at the Sloan Kettering Institute, a diverse group of nanotechnologists work on applying their knowledge of this infinitesimally small world to practical problems in cancer treatment. One ongoing project: getting cancer drugs to the right place in the body.

SPECIAL DELIVERY For a cancer drug to succeed, it has to do more than just wipe out cancer cells. The real challenge is to avoid collateral damage to normal tissues. In 2016, Dr. Heller and his team devised a novel strategy for addressing this problem. They built nanomedicines Daniel Heller, above, with his models of nanoparticles. — tiny particles filled with cancer drugs — to target To scale, these tiny objects would have diameters one the blood vessels that feed tumors, bringing the fight thousandth that of a human hair. right to the source. “There is a lot of potential in nanotechnology,” he says. “If the particles can bring a drug to the site of a metastatic disease, people won’t feel as many side effects, and it could be a more cause roughly 90 percent of cancer deaths. “We know effective therapy.” that cancer cells can come into contact with P-selectin to begin the formation of metastatic tumors,” Dr. Heller Dr. Heller’s nanoparticles are made out of a very says. “So in effect, we’re hacking into the metastatic abundant and cheap substance called fucoidan, process in order to intercept the cells and destroy the which is extracted from brown algae that grows cancer with drug-loaded nanoparticles.” in the ocean. Fucoidan has a natural affinity for a molecule called P-selectin found on tumor blood In addition to improving drug targeting, Dr. Heller’s lab vessels. In effect, P-selectin serves as a kind of is also exploring implantable sensors that could detect molecular Velcro for the nanoparticles, which stick cancer biomarkers at the moment they appear — working to the blood vessels and release their toxic payload. like a kind of Fitbit for cancer detection.

What’s more, P-selectin is especially prevalent in “This may sound like science fiction now,” he says, “but blood vessels that nourish metastatic tumors, which we’re working to make it reality.”

14. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

WAVE OF MUTILATION MSK researchers are learning that sometimes, with the right nanoparticle, you don’t even need to add a drug. Physician-scientist Michelle Bradbury, along with her colleague Michael Overholtzer, has discovered that very small silica nanoparticles are capable of killing cancer cells on their own. Under the right circumstances, the nanoparticles induce a form of programmed death in the cancer cells called ferroptosis (literally, death by iron) that spreads from cell to cell in a wave-like manner.

The nanoparticles, called C dots, are very small silica shells containing molecules of dye that glow MICHELLE BRADBURY brightly when hit by light of a specific wavelength. This allows doctors to trace their location as they move throughout the body. The nanoparticles, which are FDA approved for use in humans, can be tagged with molecules that bind to a receptor on the surface of cancer cells, lending them to powerful diagnostic and therapeutic applications.

In a 2016 study published in the journal Nature Nanotechnology, Dr. Bradbury and colleagues showed that C dots significantly shrank tumors and inhibited tumor growth in cancer-bearing mice. “This is the first time we have shown that the particle has intrinsic anticancer effects,” Dr. Bradbury says. “And it does so without associated toxicity.” The researchers are collaborating with clinicians to design new therapies using this approach in combination with standard therapies to treat cancer in people.

The background image at right is a representation of nanoparticles, like those developed by Daniel Heller and Michelle Bradbury, destroying a cancer cell. The nanoparticles are shown in gray.

15. INNOVATION

CELLS 2.0: CAR T TECHNOLOGY

It takes a particular kind of chutzpah to look at a cell — perhaps the greatest evolutionary invention of all time — and see room for improvement. The scientists in MSK’s Center for Cell Engineering (CCE) are leaders in pushing the boundaries of the possible.

It was at MSK several years ago that members of the CCE, including Renier Brentjens, Isabelle Rivière, and Michel Sadelain, developed the first chimeric antigen receptor (CAR) T cells for use in cancer treatment. These genetically modified immune cells contain within them a gene that does not exist in nature. With this new gene, the cells become lethal cancer-killers, able to home in on and destroy cancer cells.

Since their clinical debut in 2010, CAR T cells have roared off the testing lot into numerous clinical trials, where they are right now saving the lives of people with several types of advanced cancer, including acute lymphoblastic leukemia and chronic lymphocytic leukemia.

“CARs are making history, beyond any doubt,” Dr. Sadelain says.

RENIER BRENTJENS ISABELLE RIVIÈRE MICHEL SADELAIN

16. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

HANS-GUIDO WENDEL

FILLING PRESCRIPTIONS AT STRESS-RESISTANT CARs THE MICROPHARMACY In 2016, MSK physician-scientist Prasad Historically, the goal of CAR T cell therapy has Adusumilli drove the field forward by engineering been to give immune cells the information they CAR T cells with greater ability to resist cancer’s need to better recognize tumor cells as foreign and defenses — what he calls “stress-resistant CARs.” attack them. But MSK researchers are learning that these chimeric cells have other uses too. Cancer cells under attack produce a molecule called PD-L1 that engages a brake on the T cells MSK scientist Hans-Guido Wendel showed and shuts them off. Taking a cue from other that these cells can function as on-site “micro- work being done in immunotherapy at MSK, Dr. pharmacies,” churning out proteins for therapeutic Adusumilli engineered the T cells to contain a effect. The new technique, which was reported decoy brake, which allowed them to continue in the journal Cell in September, illustrates functioning for longer. The novel approach — an untapped potential of CAR T cells to act as which was featured on the cover of the Journal of targeted delivery vehicles by revamping them to Clinical Investigation — could lead to more long- produce anticancer agents. lasting clinical benefit from these “living drugs.”

“This form of treatment could be very effective Dr. Adusumilli is translating this stress-resistant because the CAR T cells continuously produce approach to the clinic by combining checkpoint the protein right where it is needed,” says blockade therapy with CAR T cells for patients Dr. Wendel. “It could increase the on-target with mesothelioma, lung, and breast cancers. In therapeutic activity and also reduce side effects March, he organized a first-of-its-kind symposium of cancer treatment because it’s restricted to the on CAR T cell therapy that brought together tumor sites.” scientists from around the world to discuss this emerging technology and bring them up to speed.

The background image, from the lab of Prasad Adusumilli, shows chimeric antigen receptor (CAR) T cells, in green, that have been engineered to recognize a protein called mesothelin on a cancer cell. PRASAD ADUSUMILLI The CAR cells are attacking the cancer cell, in blue.

17. INNOVATION

MOLECULAR MOVIES: CRYO-ELECTRON MICROSCOPY

They say a picture is worth a thousand words. James Watson — the co-discoverer of the structure of DNA — would no doubt agree. It was after seeing one particular picture of DNA, generated by his colleague Rosalind Franklin, that a light bulb flashed in his mind. “The instant I saw the picture my mouth fell open and my pulse began to race,” Dr. Watson recalled in his memoir, The Double Helix.

The picture that so stirred Dr. Watson’s imagination was created by a process called x-ray crystallography. Beams of x-rays are aimed at a biological specimen, and the diffraction pattern of the rays, captured on film, can be used to decipher the placement of atoms in the molecule. For nearly a century, x-ray crystallography has been the gold standard for determining the structure of biological molecules. STEPHEN LONG JOAN MASSAGUÉ But no more. There’s a new imaging technology in CHRISTOPHER LIMA town that is revolutionizing biology, and in 2016 it arrived at MSK. RICHARD HITE NIKOLA PAVLETICH Called cryo-electron microscopy (cryo-EM), the technology is to x-ray crystallography what an iPhone is to a landline. With cryo-EM, scientists can take razor-sharp pictures of cellular structures at the atomic scale. The technique also eliminates the need to first make a crystal out of the substance — which is the foundation of x-ray crystallography and can be incredibly time Top: The researchers pose with consuming and not always successful. the Titan Krios cryo-electron microscope recently installed at MSK. The technology greatly BIGGER, BETTER enhances scientists’ ability to “Cryo-EM is changing the field,” says Stephen understand the structure and Long, a structural biologist in the Sloan Kettering function of biological molecules. Background image: The three- Institute (SKI) whose research focuses on the dimensional structure of an structure of ion channels in cells. “It’s changing enzyme, as determined by cryo- the kind of problems we can address. We can address electron microscopy. Courtesy of Sriram Subramaniam and bigger things. We can address protein complexes.” colleagues at NIH.

18. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MSK INNOVATORS

DANA PE’ER CHAIR, COMPUTATIONAL AND SYSTEMS BIOLOGY PROGRAM, SLOAN KETTERING INSTITUTE Proteins that sit in cell membranes and large, multi-protein complexes have always been difficult, if not impossible, to study with x-ray crystallography — they don’t easily form You joined MSK as Chair of Computational and crystals. But with cryo-EM, they can be tackled Systems Biology in 2016. What exactly does a in a matter of weeks. computational biologist do? Computational biology is biology with Dr. Long likens the difference to a mountain another toolkit, one that allows me to design climber hiking up a mountain with a pair of mathematical algorithms — essentially complex skis versus being dropped off at the top by equations — that teach computers to filter data a helicopter. “That difference lets you ski and to find important patterns in that data. new slopes — study more intricate and more Math is rigorous and biology is messy. The trick dynamic protein complexes,” he says. is to find the pattern in the mess, and machine learning helps us do that. While cryo-electron microscopes have actually been around for more than 25 years, their How are you using novel techniques to do that? utility to biology was limited. The technological My goal is to apply studies of cell heterogeneity breakthrough that suddenly vaulted them to using single-cell analysis and other technologies prominence was the development of cameras to understand cancer and improve personalized that could record subtle atomic movements. therapy. When we talk about computational biology, we are talking about precision medicine — “The data are recorded as a movie, like using a big goal is to enhance that field. the burst mode on your iPhone,” explains Nikola Pavletich, Chair of the Structural What drives you scientifically? Biology Program in SKI. “If you correct for each I feel like a kid in a candy shop. I’ve wanted to particle’s motion, you get super-sharp images. be a scientist since I could speak. The beauty And that’s the revolution in cryo-EM.” of science inspires me, and it was the elegance of mathematical logic that made me fall in love The incredible power of the technique was with math. Of course, discovery is very hard — I revealed in a recent study by Richard Hite, work 80 to 90 hours a week. But my skills could a new member of SKI’s Structural Biology help cure cancer, so I feel morally committed to Program. As reported in the journal Nature, this work. Cancer also took my mother, so it’s he and his colleagues used cryo-EM to show personal. It’s a wonderful feeling to be able to how certain viruses can hijack the way contribute to understanding this disease and how harmful invaders are normally sensed by to better treat patients. That makes it all worth it. the immune system. The finding could have implications for understanding how cancer evades immune detection.

19. INNOVATION

WHAT YOU EAT: “The time has come for cancer biologists to dust METABOLISM & off their biochemistry textbooks,” Craig Thompson, MSK’s President and CEO, wrote in an influential EPIGENETICS article titled “Cancer’s Sweet Tooth” in an issue of the journal Cancer Cell several years ago. “It seems there are a few chapters that still need to be written.”

Dr. Thompson was referring to then-recent discoveries linking metabolism — the biochemical pathways that cells use to obtain nutrients and energy — and cancer. Since then, he has been at the vanguard of this return to metabolism among cancer biologists. He has also served as one of the field’s greatest champions, encouraging others to give metabolism a second look.

One person who has taken up the challenge is Ming Li, an immunologist with the Sloan Kettering Institute (SKI). Dr. Li studies T cells, those trusty guardians of the immune system that daily protect us from dangerous infections, and even cancer.

In 2016, Dr. Li published a report in Science showing that what a T cell “eats” changes the genes that are turned on or off in the cell. When T cells sense danger, they shift their metabolism to something called the Warburg effect, which prods the cells to suck up a sugar called glucose. This change in metabolism, in turn, leads to a change in gene expression. Without these shifts in behavior, the cells would not be able to mount a sustained attack against their foes.

Somewhat devilishly, cancer cells also use the Warburg effect to obtain nourishment, meaning they directly compete with the cells that might combat them. Dr. Li’s results underscore the need to think about cancer treatment in the context of other cells that might be affected by a treatment T cells like those that targets metabolism. “When it comes to cancer shown here help treatment, we should not just focus on the tumor defend the body against infections cells, but also the tumor environment, and consider and cancer. its impact on the immune system,” he says.

continued

20. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

“THE TIME HAS COME MSK INNOVATORS FOR CANCER BIOLOGISTS TIMOTHY TO DUST OFF THEIR CHAN BIOCHEMISTRY DIRECTOR, IMMUNOGENOMICS TEXTBOOKS.” AND PRECISION ONCOLOGY PLATFORM – CRAIG THOMPSON PRESIDENT AND CEO, MEMORIAL SLOAN KETTERING What’s the idea behind the Immunogenomics and Precision Oncology Platform (IPOP), formed at MSK in 2016? In IPOP, precision oncology and immuno- oncology merge. Our goal is to pinpoint why immunotherapies work well for some people and not others, and to use this information to design new combinations of therapies.

Tell us about your recent study in Nature Genetics. CRAIG THOMPSON Our lab had previously shown that the more mutations a cancer has, the more likely it is to respond to immune checkpoint inhibitors. That led to the idea that a tumor’s mutational load is an important determinant of its responsiveness to immunotherapy. This now widely validated concept is already being used for clinical testing. In this study, we identified mutations in two genes that were associated with a good response to immunotherapy. This was the first time that patients with mutations in individual genes were shown to benefit from immunotherapy.

How did the patients with these mutations do compared with those without? For all patients, the average response rate was about 15 percent. But in patients who had mutations in those genes, the response rates to immunotherapy were much higher, 60-65 percent. Many of those patients had complete, long-lasting responses.

If we can identify which patients have these mutations, we may find that the drug is effective in subgroups of a variety of cancer types — such as prostate, kidney, and head and neck cancers — that typically have low response rates to immunotherapy.

21. INNOVATION

MING LI

Ming Li, left, with lab member Emily Kansler, a student at MSK’s Gerstner Sloan Kettering Graduate School of Biomedical Sciences.

“WHEN IT COMES TO DNA PACKAGING CANCER TREATMENT, This discovery about T cells and metabolism was WE SHOULD NOT JUST remarkable for another reason. The change in gene FOCUS ON THE TUMOR expression that Dr. Li observed came about from the way DNA is packaged in the nucleus, spooled around CELLS, BUT ALSO THE proteins called histones. This is what experts refer to TUMOR ENVIRONMENT.” as an epigenetic change — a change in gene expression that is not due to a change in the sequence of DNA – MING LI itself. Researchers at MSK and elsewhere are excited IMMUNOLOGIST, to learn more about epigenetics because many types SLOAN KETTERING INSTITUTE of cancer have these changes. They hope that it may be possible to turn a cancerous cell back to normal by undoing certain epigenetic changes — an easier feat than mending mutated DNA.

MSK now has a talented cadre of researchers investigating the mechanics of epigenetics, and an entire center devoted to the subject. Several new investigators have recently joined the epigenetics team, including Yael David, a promising chemist with SKI’s Chemical Biology Program. Her lab uses novel chemical methods to understand epigenetic

22. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

YAEL DAVID

Yael David (left) with graduate student Adewola Osunsade.

mechanisms in cells, with the ultimate goal of developing effective therapies for cancer and other diseases.

One recent paper, published in Nature Chemistry, caused a stir among researchers. Dr. David showed how she could use molecules called inteins — self-splicing bits of protein — to make precise changes to the histones around which DNA is wrapped. Inteins have high affinity for each other, and when they meet in a cell, they abscond from the scene, linking the two molecules to which they were previous attached. “It’s really a beautiful way to engineer proteins in a cell,” she says.

Dr. David is a recipient of a Josie Robertson Young Investigator Award, which supports exceptional young scientists who, early in their careers, have attained significant insights into cancer and devised innovative approaches to prevention and treatment.

23. INNOVATION

INNOVATIONS IN:

24. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

Surgeon Mario Leitao (center), shown here with surgical fellows, is the Director of the Minimal Access and Robotic Surgery program at MSK. He performs minimally invasive procedures for women with gynecologic cancers.

25. INNOVATION

Sometimes, the most important advances in patient care come from challenging established ways of thinking and reconsidering intractable problems and conventional ways of solving them.

At MSK, our scientists and clinicians are continually searching for ways to give our patients the exact care they need — nothing more, nothing less. They’re also experts at bringing advances in treatment from the lab to the infusion chair, operating suite, and exam room as fast as possible.

“IT ALL EMANATES FROM A DEEP CONVICTION THAT THE WAY TO SAVE MORE LIVES AND THE WAY TO HELP PATIENTS AND THEIR FAMILIES IS BY MAKING SURE THAT WE QUICKLY MOVE ALL THE DISCOVERIES THAT ARE HAPPENING IN OUR BASIC RESEARCH LABS TO THE CLINIC. THAT CAN ONLY HAPPEN HERE. IT’S INNOVATION WITH A HUMAN FACE.”

– JOSÉ BASELGA PHYSICIAN-IN-CHIEF AND CHIEF MEDICAL OFFICER

26. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

HUNTING BAD BACTERIA: PREVENTING GVHD

ERIC PAMER

Marcel van den Brink and Eric Pamer study the complex interactions between the microscopic organisms that inhabit MARCEL VAN DEN BRINK the body and their human environment.

Bone marrow transplants (BMTs) save scores of lives cancer. But because these therapies destroy the bone and are often among the last options for some cancer marrow, they also damage the immune system. To prevent patients. But the intensive regimen that comes with infections while their newly transplanted immune system the procedure — which involves replacing a patient’s rebuilds, BMT patients are given antibiotics. diseased bone marrow with healthy cells from a donor — can introduce its own life-threatening complications. Drs. van den Brink and Pamer found a link between the antibiotics a patient receives and the risk for GVHD. In 2016, a group of MSK scientists including Marcel They made this connection by analyzing fecal samples van den Brink, Head of the Division of Hematologic to study the microbiome, the genetic makeup of all the Oncology, and Eric Pamer, Head of the Division of microorganisms that colonize the body. Subspecialty Medicine, reported a surprising discovery about one of the most severe and dreaded consequences A COMPLEX RELATIONSHIP of BMTs: graft-versus-host disease, or GVHD. The Broad-spectrum antibiotics kill a wide range of condition occurs when immune cells from the donor bacteria, making them effective at fighting off a attack the patient’s healthy tissues, often in the lining multitude of infections. But this firepower also of the gastrointestinal tract. increases the chance that beneficial bacterial strains will be destroyed as well. When this happens, other, Before a BMT, patients are given high doses of potentially harmful varieties can take over. chemotherapy and sometimes radiation to wipe out the

27. INNOVATION

Drs. van den Brink and Pamer discovered that the type of antibiotics patients are given to combat infection may affect the likelihood they will develop GVHD, as well as the severity of this complication if it occurs. As it turns out, some of the gut bugs that flourish after treatment with certain antibiotics are a major contributor to GVHD.

“Since 2009, we’ve been collecting samples from our patients who are undergoing transplants and using the data from their intestinal microbiomes to learn what’s happening in the gut,” says Dr. van den Brink.

The findings could help lessen patients’ risk of suffering from a potentially fatal complication as well as improve the effectiveness — and toxicity — of cancer therapies. They also underscore the importance of considering the global scope of cancer’s effect on the body, and in looking for answers in unexpected (and teeny-tiny) places.

Ingrid Leiner, manager of the Pamer lab, handles fecal samples in a specially designed anaerobic chamber. The environment within the chamber is designed to mimic the oxygen-depleted gut, allowing the researchers to cultivate many microorganisms that typically reside there.

28. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

29. INNOVATION

BETTER TOGETHER: TARGETING BRAIN TUMORS

KATHRYN BEAL

To mark his 50th birthday in the fall of 2015, Derrick oncologist Paul Chapman and radiation oncologist Queen set a goal to get in the best shape of his life. Kathryn Beal, who specialize in treating these He was already a healthy eater, avoided alcohol, tumors — and in offering patients hope when their and generally took care of himself. So when he options have run out. experienced a series of severe, debilitating headaches in May 2016, he knew immediately that something They are leading the development of a new was very wrong. method to combat brain tumors and metastases: a combination of immunotherapy drug treatment Derrick went to his primary care doctor, who sent and stereotactic radiosurgery (SRS), both him for an MRI. “I was sitting in the waiting room techniques MSK pioneered. expecting them to call my name, figuring they would say I was good to go home,” he said. But instead, A POWERFUL COMBINATION “they took me into an office where there were images In SRS, doctors are able to shape a highly targeted, of my brain all over the screen. The doctor was at a intense dose of radiation to the precise three- complete loss for words.” dimensional outlines of a tumor using advanced imaging and sophisticated computer guidance. The diagnosis was as bleak as it was unexpected: This cuts down on damage to the rest of the brain stage IV metastatic melanoma. Derrick had one and limits side effects, as compared with typical tumor in each lung and three in his brain, including radiation techniques. one the size of a clementine. Their twist was to combine SRS with an After surgery to remove the largest of the brain immunotherapy drug called pembrolizumab tumors, Derrick came to MSK to see medical that helps the immune system to recognize and

30. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

attack tumors. While the drug targets tumors Derrick was one of the patients whose disease throughout the body, SRS is used to eliminate simply vanished, both in his brain and his lungs. metastases in the brain. Historically, for a “After the combination treatment [of SRS and patient with melanoma and brain metastases, pembrolizumab], you couldn’t see them anymore,” the median survival was four months. With this he says. “I feel a little bit like Jimmy Stewart in It’s new combination treatment, about 20 percent a Wonderful Life, like I got a second chance.” of these patients appear to be completely cured, although further long-term follow-up is required, 9/21/16 11/28/16 Dr. Beal says.

At the American Society for Radiation Oncology annual meeting in 2016, she presented results of the 20 initial patients treated with concurrent SRS and pembrolizumab who had stage IV melanoma and brain metastases. Roughly 65 percent had either a complete response — the disease disappeared entirely — or a partial response just six to eight weeks after their radiation treatment. The results are even more startling when Top: Derrick Queen, with Kathryn Beal, had a complete compared with SRS alone, for which only about response to combination therapy for metastatic 3 percent of patients see such an obvious response melanoma. Bottom: The image at left shows Derrick’s so rapidly. And the response seems to be lasting. brain with a clementine-size tumor in September 2016. By November, after treatment with the immunotherapy drug pembrolizumab, the tumor had vanished.

31. INNOVATION

SETTING THE STAGE: EASING LYMPHEDEMA

MARIO LEITAO

Sometimes, the side effects of cancer treatment can More than a decade ago, surgeon Nadeem be even more debilitating than the cancer itself. Abu-Rustum pioneered the use of a technique One such complication is lymphedema, a painful called sentinel lymph node mapping (SLNM) swelling of the limbs that can seriously impact to detect whether cells have escaped a tumor someone’s daily life, even when cancer treatments and spread to the sentinel nodes — the first are long over. lymph nodes to which the cancer is likely to travel. This technique significantly reduces the Gynecologic surgeons are using their combined number of lymph nodes that need to be removed, decades of experience to help women with thus drastically lowering a patient’s chances of gynecologic cancers avoid this unbearable developing lymphedema. condition, which occurs when lymph nodes are damaged or removed. SIMPLE SOLUTION, OUTSIZE IMPACT SLNM is strikingly low-tech: Just before the Traditionally, surgeons treating women with operation to remove the tumor, the surgeon injects early-stage gynecologic cancers remove numerous dye at two precise locations in the patient’s cervix. lymph nodes in the pelvis — sometimes as many Lymph fluid carries the dye to the sentinel nodes, as 50 — to examine them for cancer cells that may making them easily identified. They’re removed, have spread there. The more lymph nodes that are along with the tumor, and examined for cancer removed, however, the higher a patient’s chances cells. If none show up, usually no additional nodes for lymphedema. Because many women with need to be removed. If they do, the surgeon may this stage of disease are in their 40s and 50s, the remove more nodes, and the patient may need condition can plague them for decades. chemotherapy or radiation.

32. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MSK INNOVATORS

ELIZA GEER MEDICAL DIRECTOR, PITUITARY & SKULL BASE TUMOR CENTER

The Skull Base Tumor Center was established at MSK in 2016, and you were brought in to help lead it. What are the biggest benefits to patients of having such a specialized group at MSK? These types of tumors are technically benign in most cases, but there are many that are very locally invasive and aggressive. And because NADEEM ABU-RUSTUM of the location, which is right behind the eyes and near the nerves that move the eyes — precious real estate — those tumors are hard to treat. That’s why these patients need a team of surgeons, endocrinologists like me, radiation oncologists, and neuro-oncologists working SLNM had already been used for breast cancer together to treat them. That’s what this new and some other cancers, but had not been popular center is allowing us to do. in gynecologic cancers, particularly uterine cancer. Thanks to surgeon Mario Leitao and The other obvious benefits for patients are that Dr. Abu-Rustum, that is poised to change. They they can see us all during one visit, at the same published a study in the journal Gynecologic time and place. We also coordinate their care Oncology that showed that for early-stage and have biweekly tumor boards, during which endometrial cancer, the most common type of we go over all the cases and look at the scans uterine cancer, SLNM works as well as traditional with radio-neurology and discuss the treatment lymph node removal for detecting cancer spread. together. It really is a collaborative treatment. There is no difference in how long patients survive. This result could make SLNM the standard of care What’s your specific role within the new center? for these patients. I coordinate and guide the care. Before surgery, I’m involved in diagnosing the patient — which “This finding could truly change how endometrial can be very challenging in some cases. It requires cancer is treated, improving patients’ quality of expertise, due to the various neuroendocrine tests life without placing them at risk for undetected we run. Also, in terms of determining the exact cancer,” says Dr. Leitao. “The findings are going location of the disease, sometimes these tumors to bring sentinel lymph node mapping to the are very small and you can’t see them on an MRI. forefront as a valid option for many more patients who will be spared these debilitating side effects.” After surgery, many patients need to continue to have treatments, like radiation or medication, before they’re in remission. We also offer new medical therapies through our ongoing clinical Mario Leitao and Nadeem Abu-Rustum often operate as a team when they perform sentinel lymph node mapping for trials. With many of my patients, I tell them I’m endometrial cancer. going to follow them forever!

33. INNOVATION

ON LOCATION: TRACKING LUNG TUMORS

ANDREAS RIMNER

Delivering the exact right level of radiation to The technology has been used successfully for a tumor as precisely as possible is complicated years to treat people with prostate cancer, and is enough. So what happens when that tumor is a already approved by the FDA for use in several moving target? other locations in the body. MSK is among a handful of centers performing the first clinical Such is the case with lung tumors, which are trials using this system for lung cancer. notoriously difficult to treat with radiation. With every breath, a patient’s lungs expand and DEEP BREATHING contract, shifting the location of a lung tumor just It also represents a huge improvement over past enough to increase the chance that radiation may efforts to map tumors and synchronize patients’ miss the cancer cells and damage normal tissue. breathing during radiation therapy. One trial led by Dr. Rimner and colleagues tests the Calypso To address the issue, radiation oncologist Andreas system in combination with a technique called Rimner is studying the use of an internal tumor- deep inspirational breath hold, which requires tracking device for patients with lung cancer called the patient to hold his or her breath for about 20 Calypso® GPS for the Body. It monitors a tumor’s seconds while the radiation is being delivered. A location during the treatment session using tiny second trial is testing the Calypso system during markers implanted in the lungs that act as beacons. treatments when the patient breathes normally, The markers signal to an external tracking system providing an option for people who are unable to that produces a 3-D representation of the tumor’s hold their breath long enough. location at all times. If the tumor moves outside of a very small field, the machine delivering the Although the results of both trials have not yet radiation automatically switches off. been fully analyzed, Dr. Rimner says he and his colleagues are pleased with how the Calypso The precision of the approach also facilitates the system has been working thus far. use of higher radiation doses to the tumor, with a greater chance for success and fewer side effects, “Knowing that this approach has already been since a smaller target area can be treated without shown to be safe and effective in other cancers, overdosing the normal tissue around it. we’re optimistic it will be incorporated into radiation treatment for lung cancer patients in the near future,” he says.

34. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MSK INNOVATORS

LUIS DIAZ HEAD, DIVISION OF SOLID TUMOR ONCOLOGY, DEPARTMENT OF MEDICINE

What led you to medicine, and to treating pancreatic and colon cancers in particular? I was always very interested in research, but at the same time, I was also interested in making an impact on patients and finding ways to help them. The combination of science and clinical care to help patients in desperate need led me to oncology.

The patients we see are the tough ones: They’re facing a potentially lethal disease. I like helping patients who really, really need help.

How are advances in genomics and precision medicine changing how we treat these diseases? Combining immunotherapy and targeted treatments will be key in finding ways to treat patients. I’m also very keen on precision medicine for cancer prevention, to detect risk.

With my colleagues, I am developing a “molecular pap smear” to diagnose early-stage ovarian and endometrial cancers based on genetic markers — a crucial advance that would mean we could catch more instances of these cancers and begin treating them as quickly as possible. The test is currently in clinical trials. My hope is that it will be part of the standard of care within the next few years.

What else will you be doing in your role, which you started in 2016? I’ll be working to improve mentorship for our young scientists and communication between Andreas Rimner uses researchers and departments across MSK. I’ll the Calypso GPS system to track lung tumors also be involved in projects to improve our in some patients with patients’ experience as well as their access to our lung cancer. The system unmatched cancer care. delivers targeted doses of radiation directly to lung tumors.

35. INNOVATION

A STRONG STOMACH: PREVENTING GASTRIC CANCER

“ I WAS BLOWN AWAY BY THE WHOLE CONCEPT THAT MY STOMACH COULD BE REMOVED, BUT AT THE SAME TIME, I KNEW WHAT COULD HAPPEN OTHERWISE. I WASN’T AFRAID.”

– MARGUERITE SMITH MSK PATIENT

Marguerite Smith says her eating habits haven’t changed since having her stomach removed to prevent gastric cancer. Vivian Strong (opposite) is a pioneer in the technique.

36. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

VIVIAN STRONG

In 2014, Marguerite Smith learned that she had a rare genetic mutation that put her at a 70 percent risk of developing an aggressive type of stomach cancer called hereditary diffuse gastric cancer. At just 40 years old — and with the results of a biopsy showing she was already showing early stages of the cancer — the mother of two made a crucial decision: to undergo a total gastrectomy, in which her entire stomach would be removed to eliminate her risk.

Marguerite’s brother Anthony was diagnosed with the disease in 2013; he passed away in 2015. After much research and consulting with MSK surgeon Vivian Strong, Marguerite and her husband made the decision to move forward with the surgery. “This is the first study to look at outcomes in “I was blown away by the whole concept that my these patients, and it shows that this lifesaving stomach could be removed, but at the same time, procedure need not cause a permanent disruption I knew what could happen otherwise,” she said. “I in their lives,” Dr. Strong says. wasn’t afraid.” After surgery, MSK pathologists always examine Dr. Strong removed Marguerite’s entire stomach the stomach tissue for early signs of cancer — and using robotic assisted surgery and connected her find it 97 percent of the time. esophagus to her small intestine. She also removed more than 30 lymph nodes for examination to “It’s an interesting perspective for both the patient confirm that the cancer had not begun to spread. and the doctor, in that it’s an unusual case where It hadn’t. you kind of want to find something,” Dr. Strong says. “In most cases, we do, and it often makes the “There’s a widespread misconception that you need patient feel better about having the operation. But a stomach to live, when you actually don’t,” says even if nothing is found, the high risk that cancer Dr. Strong. “This operation, in which our surgeons would eventually occur still applies.” have become highly specialized, can eliminate a major cancer threat for people with the mutation.” She adds that patients treated at MSK benefit greatly from well-experienced surgeons who began GUT FEELINGS doing prophylactic gastrectomies in 2005: “We see A study led by Dr. Strong and published in more stomach cancer here than any other hospital the Annals of Surgery in 2016 confirmed the in the country, and no other center does these effectiveness of total gastrectomy to eliminate the robotic procedures in such high volume.” risk of stomach cancer. Among the 41 patients in the study with the same mutation as Marguerite Marguerite returns annually for CT scans at who also had total gastrectomy, 85 percent Memorial Sloan Kettering Commack, near her reported their quality of life to be either as home on Long Island. All have shown no sign of expected or better than expected post-surgery. disease. “Today there are entire days that go by that I don’t even think of my surgery,” she says. “But I do think of my brother Anthony every day. He’s my hero. He and Dr. Strong.”

37. INNOVATION

INNOVATIONS IN:

38. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

Almost every cancer treatment offered to patients today has come about because of a clinical trial. By participating in clinical trials, patients get access to innovative new treatments — sometimes years before these therapies are widely available.

39. INNOVATION

Pipeline of Discovery:

Fundamental lab research into the basic biological understanding of cancer has planted the seeds that are now flourishing into an abundance of new drugs — some for cancers that haven’t seen treatment improvements in a generation. MSK investigators are among the most prolific in cultivating new cutting- edge therapies, developing them from innovative breakthroughs in the lab into actual treatments in the clinic.

And because our clinicians lead so many clinical trials, MSK patients often gain access to these life-improving drugs months or years before they are widely available, making a critical difference to them and their families.

Here are just a few of the many advances to which our researchers made contributions in 2016.

40. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

We offer trials in

therapeutic different clinical trials in 2016. 9 phases, from phase 0 to IV and pilot studies.

200 MSK HAS TRIALS FOR MORE THAN TYPES OF CANCER.

To date

drugs MSK-initiated research trials developed are running at more than at MSK have been FDA 120 unique 8 approved. institutions.

41. INNOVATION

EARLY-STAGE ROVALPITUZUMAB TESERINE DEVELOPMENT New approaches for treating small cell lung cancer, which hasn’t seen significant treatment advances since the 1980s, are showing promise. At the annual meeting of Historically, the purpose of the American Society of Clinical Oncology early-stage clinical trials was to (ASCO) in June 2016, MSK Thoracic Oncology determine safety and dose for Service Chief Charles Rudin presented results a new drug or other treatment. from an early-stage clinical trial that he led In the era of targeted therapies, of a drug called rovalpituzumab teserine these research studies are (Rova-T). The findings were published in increasingly able to show efficacy. Lancet Oncology in early 2017.

Rova-T consists of a cancer-targeting antibody linked to a chemotherapy molecule. After the antibody seeks out the cancer cell, it delivers toxic chemotherapy — a kind of smart bomb for cancer.

Among the patients in the trial with the highest levels of DLL3, the protein targeted by the antibody, more than one-third had a partial or complete response. Based on these findings, larger trials have been initiated.

Patients who had significant tumor 39% reduction in response to Rova-T

Charles Rudin cares for patients with lung cancer at MSK and also oversees a research lab focused on developing new treatment approaches.

42. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

ENTRECTINIB PU-H71 AND PU-PET In personalized oncology, one important Proteins called molecular chaperones work focus is advancing basket studies. This type by assisting other proteins. Sometimes these of trial focuses on developing drugs that chaperones become incorporated into large target a specific mutation found in a tumor, networks called epichaperomes, found only in regardless of where the cancer originated. cells undergoing a disease process.

This past year, MSK medical oncologist Chemical biologist Gabriela Chiosis developed Alexander Drilon reported combined results a way to block a key epichaperome, disabling from two such studies, demonstrating that proteins that cancer cells need to survive. Her an experimental drug called entrectinib can research resulted in a new drug, PU-H71. In a slow or stop tumor growth in patients with trial at MSK, John Gerecitano and Shanu Modi a particular kind of genetic mutation. The evaluated PU-H71 for the first time in patients. mutation, called a gene fusion, plays a role in This drug is now advancing to a phase I/II trial regulating how cells survive and multiply. for patients with metastatic breast cancer.

The two phase I trials enrolled patients with The research also led to an imaging several different solid tumors — including scan called PU-PET, which would allow lung, colorectal, and salivary gland tumors. identification of patients who could benefit After an average follow-up time of almost from this therapy. A trial is being led by a year, the majority of patients who initially radiologist Mark Dunphy. If these agents responded to the drug continued to do well. ultimately prove to be effective, it would be The studies were reported at the annual an important breakthrough for an approach meeting of the American Association for that was born and bred at MSK. Cancer Research in April.

Three gene Target of the TRKA/B/C, fusions drug PU-H71, ROS1, AND ALK targeted by HSP90 which blocks entrectinib its activity

Alexander Drilon is a member of MSK’s Developmental Gabriela Chiosis’s lab in the Chemical Biology Program Therapeutics group, which aims to bring new drugs to uses chemical biology techniques to understand, diagnose, patients with all types of cancer. and treat cellular processes associated with chronic stress.

43. INNOVATION

LATE-STAGE ENASIDENIB DEVELOPMENT Most cancer drugs are designed to kill cancer cells, but MSK researchers are developing a treatment designed to rehabilitate them, turning them back into normal cells. MSK Late-stage clinical trials are hematologic oncologist Eytan Stein is leading designed to determine whether a research on this type of targeted therapy, new treatment is more effective called enasidenib, for a variety of blood than the current standard of care. cancers caused by mutations in a gene called Outcomes from patients receiving IDH2, primarily acute myeloid leukemia and the new treatment are compared myelodysplastic syndrome. with those of patients receiving the standard treatment. Enasidenib works by blocking the enzymes made from this mutant form of IDH2, which prevent normal blood stem cells from developing as they should. Based on early studies led by Dr. Stein, in late 2016 a New Drug Application for enasidenib was submitted to the FDA and the drug was granted priority review. The drug is being tested in two trials at MSK.

Protein whose mutations allow IDH2 certain cancer cells to grow

Eytan Stein is leading a number of clinical trials for patients with leukemia and myelodysplastic syndrome.

44. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

WT1 VACCINE CAR T The cancer-causing protein WT1 is an Cell therapies are a rapidly growing area of important target for cancer therapy. MSK cancer research. Renier Brentjens, Isabelle investigators led by David Scheinberg have Rivière, and Michel Sadelain pioneered one been developing vaccines to target WT1 for of the most promising of these approaches, more than a decade. At the ASCO meeting, chimeric antigen receptor (CAR) T cell two phase II studies reported promising immunotherapy. (Read more about MSK’s results for this vaccine. work in this promising area on page 16.)

One, led by Marjorie Zauderer, evaluated the This therapy involves training a patient’s own safety and benefit of giving the vaccine to T cells to recognize cancer, then setting them patients with mesothelioma. There were few loose to do their work. MSK is leading trials side effects, and the study showed survival to evaluate CAR T cell therapy for leukemia improvements. With few current options and lymphoma. For these blood cancers, T for mesothelioma, this vaccine would be an cells are engineered to recognize a protein important advance. Another, presented by called CD19, found on the surface of blood Peter Maslak, reported that for patients with cells called B cells. A study led by Jae Park acute myeloid leukemia, the WT1 vaccine demonstrated the potent antitumor activity stimulated a specific immune response and of these CAR T cells in patients with acute lengthened survival. lymphoblastic leukemia. Nearly 80 percent achieved a complete response within 20 days Based on these findings, phase III trials are of treatment. planned for the WT1 vaccine in both of these cancers. MSK investigators are continuing to Additional MSK studies employ T cells evaluate the vaccine for other types, including designed to recognize different proteins ovarian cancer and multiple myeloma. found in other cancers.

Cancer vaccine that Protein found on helps the immune the surface of a WT1 system to fight the CD19 type of blood cell disease called B cells

David Scheinberg is Chair of the Molecular Pharmacology Hematologic oncologist Jae Park is leading Program, which develops novel immunotherapeutic immunotherapy studies that employ CAR T cells. agents and targeted nanodevices, among other things.

45. INNOVATION

FDA-APPROVED OLARATUMAB DRUGS Soft tissue sarcoma has few treatment options beyond surgery, which makes the targeted therapy olaratumab (Lartruvo™) — the first drug approved for the initial treatment of this After treatments receive FDA cancer in more than 40 years — noteworthy. approval, they become available to William Tap, who specializes in this disease, patients outside of clinical trials. led the trial that resulted in FDA approval in This means that cancer patients October 2016. everywhere eventually can benefit from research conducted at MSK. In that study, 133 people with metastatic sarcoma received either the chemotherapy drug doxorubicin (the standard treatment) or doxorubicin with olaratumab. The average survival of patients who got the combination was 26.5 months, compared with 14.7 months for patients who got doxorubicin alone.

Olaratumab is an antibody that binds to and blocks a receptor called PDGF-alpha on the surface of certain cancer cells and in the tumor microenvironment (the area surrounding the tumor). The receptor contributes to cancer’s growth and spread.

Average number of months that olaratumab extended 11.8 survival in patients with soft tissue sarcoma

Medical oncologist William Tap leads a dedicated team that understands the nuances of soft tissue sarcoma, an uncommon and challenging malignancy.

46. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

NIVOLUMAB ATEZOLIZUMAB An international trial led by Anas Younes, In May 2016, the FDA approved the novel Chief of MSK’s Lymphoma Service, resulted immunotherapy drug atezolizumab in the approval in 2016 of the first blood (Tecentriq®) for patients with metastatic cancer treatment aimed at unleashing an urothelial carcinoma, the most common type antilymphoma immune response. Nivolumab of bladder cancer. The drug, which represents (Opdivo®) — which was already approved for the first new treatment for this cancer in more certain forms of melanoma, kidney cancer, than 20 years, was approved based on a large and lung cancer — is a type of drug called multicenter clinical trial led by MSK medical a PD-1 inhibitor. MSK medical oncologist oncologist Jonathan Rosenberg. Alexander Lesokhin co-directed the early clinical testing of the drug, which works by Results from that trial showed that releasing the brakes on the body’s immune atezolizumab shrank tumors in a significant system. This allows it to mount a stronger portion of patients, and the benefit appeared attack against cancer. to be lasting in many people: Among patients in the clinical trial who had anticancer The trial included 80 patients whose Hodgkin responses, 84 percent were still responding lymphoma had returned even after the most after about one year. advanced treatment possible — a stem cell transplant followed by treatment with a drug Atezolizumab is another member of the class called brentuximab vedotin. Nearly two-thirds of drugs called checkpoint inhibitors. The of them responded to nivolumab (meaning molecule it targets, called PD-L1, prevents they had complete or partial remission of the immune system from recognizing that their disease), with the response lasting the cancer cells pose a threat. When PD-L1 an average of one year, and many patients is blocked, this enables the body’s immune continuing to do well for much longer. system to recognize and attack the cancer.

Patients who had complete Patients who responded or partial remission of their to atezolizumab who 66% disease after treatment 84% were still responding a with nivolumab year later

Investigator Anas Younes is working to accelerate the Jonathan Rosenberg is focused on developing new development of new treatment strategies for patients treatments that target the growth and progression of with Hodgkin and non-Hodgkin lymphoma. bladder cancer.

47. INNOVATION

INNOVATIONS IN:

48. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

The newly redesigned fourth floor of Memorial Hospital was designed specifically for neurology, neurosurgery, and orthopedics patients, who have unique challenges in regaining their mobility after surgery. Physical therapists like Nicole Kasven (right) and Amanda Molnar are an important part of these patients’ care teams.

49. INNOVATION

Just as no two cancers are exactly alike, no two people have the same cancer care needs. MSK put this foundational principle to work in several spaces in 2016 — some overhauls of existing facilities and some built from the ground up, but all designed to improve patients’ and caregivers’ experiences.

The Department of Nursing played a significant role in the creation of these spaces, including M4 and MSK Monmouth. This year, MSK also achieved Magnet® designation, a prestigious recognition of nursing excellence and quality patient outcomes.

“ OUR ACHIEVEMENT OF MAGNET® RECOGNITION PROVIDED CONFIRMATION OF OUR NURSES’ SUPERB PERFORMANCE AND DEDICATION. EXCELLENCE IS EVIDENT IN EVERY ASPECT OF THEIR WORK, FROM THE COMPASSIONATE, KNOWLEDGEABLE, HANDS-ON CARE THEY DELIVER TO THEIR INTEGRAL ROLE IN GUIDING THE DEVELOPMENT OF THE FACILITIES IN WHICH THEY DELIVER IT.”

– ELIZABETH MCCORMICK CHIEF NURSING OFFICER

50. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MEMORIAL HOSPITAL FOURTH FLOOR (M4)

The fourth floor of Memorial Hospital got a state- of-the-art face-lift in 2016 when it was redesigned specifically for neurology, neurosurgery, and orthopedics inpatients. Improvements for this specialty patient population included mirrors and special lighting along the hallways to help patients regain their mobility as well as to act as distance markers as they walk the halls. Program enhancements included adding telemetry monitoring and expanded EEG monitoring. A centrally located workspace for doctors and nurses was added to allow for accessibility and easy collaboration on patient care.

51. INNOVATION

COMMACKMSK LONGCOMMACK ISLAND

Much of MSK Commack was expanded and refreshed in 2016. Beyond the brighter waiting areas and more comfortable treatment rooms, the upgrade increased space for laboratory services, which means patients can have more testing done on site and receive test results more quickly. It also brought support services, such as acupuncture and genetics counseling, and interventional radiology to MSK Commack patients.

52. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MSK MONMOUTH

Memorial Sloan Kettering Monmouth opened its doors to residents of the Garden State in December 2016. The facility offers private infusion rooms, a full rehabilitation gym, on- site interventional radiology and radiation treatments, endoscopy, and advanced lab capabilities. And in a first for MSK outside of Manhattan, patients can also have outpatient surgical procedures at the facility.

53. INNOVATION

TEEN AND YOUNG ADULT LOUNGE

54. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

MSK INNOVATORS

ANDREW KUNG CHAIR, DEPARTMENT OF PEDIATRICS

The Lounge, a space designed for MSK’s patients between the ages of 16 and young Precision medicine is increasingly becoming adulthood, is a part of the Teen and Young the new face of treatment. How does it apply to Adult Program, or TYA@MSK. The program childhood cancer? was created in 2016 for patients to relax, build The goal of precision medicine is to improve the friendships with others in similar situations, technologies and discoveries that have come out and get some distance from their medical of the laboratory and bring those to the patient. issues. The Lounge has video game systems, Precision medicine as we practice it uses the board games, books, and a wall-size projector latest technologies to characterize the child’s to show movies and TV shows, along with cancer, to figure out precisely what went wrong a full snack bar. TYA@MSK also offers the that resulted in the development of the disease. Peer-2-Peer program, which connects current Then we tailor and personalize the treatment patients with survivors, as well as a secure plan to be as precise as possible, being mindful mobile app that connects patients, provides to minimize the toxicities as we treat the child. resources, and shares events. You took on your role as Chair in 2016. What’s your vision for the department? My short-term and long-term goals are the same: to take the foundation of excellence and reach even further to find better ways to treat children, and ultimately find ways to return kids back to normal life as quickly and as meaningfully as possible.

How do you cope with the emotionally intense aspects of your job? You really have to be able to see the silver lining. In many cases, even if a child is not cured, there’s so much we can do in extending his or her life and making sure that life is as comfortable as possible. We have to be able to see that during those days when the roller coaster is on the downswing.

Being a pediatric oncologist is very rewarding. Just walking into the clinic and seeing the kids running around and playing, you would not know that these children had cancer but for the fact that they’ve lost their hair from the chemotherapy. That resilience and vigor is really inspiring.

55. INNOVATION

STATISTICAL PROFILE

12 13 14 15 16

PATIENT CARE

Patient Admissions: Adults 23,139 20,773 20,640 21,064 21,708 Patient Admissions: Children 1,459 1,553 1,504 1,403 1,370 Total Admissions 24,598 22,326 22,144 22,467 23,078 Total Patient Days 149,368 144,345 146,855 151,827 160,072 Average Patient Stay (days) 6.1 6.5 6.6 6.8 6.9 Bed Occupancy Rate (1) 87.0% 83.0% 84.3% 90.9% 92.5%

Outpatient MD Visits: Manhattan 436,510 463,724 480,260 489,897 512,142 Outpatient MD Visits: Regional Network 104,964 108,198 113,699 136,506 153,451 Total Outpatient Visits 541,474 571,922 593,959 626,403 665,593 Screening Visits 15,519 12,826 10,282 22,403 23,497 Surgical Cases 19,691 20,465 20,420 21,368 23,066

Radiation Treatments & Implants: Manhattan 60,289 61,335 62,375 60,804 63,392 Radiation Treatments & Implants: Network 50,476 53,660 55,229 58,041 59,485 Total Radiation Treatments & Implants 110,765 114,995 117,604 118,845 122,877

Diagnostic and Interventional Radiology Procedures 391,187 416,360 435,501 466,848 498,372 Clinical Investigation Protocols (2) 657 735 776 879 1,072

(1) Based on adjusted bed count (2) Excludes studies closed to accrual

56. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

12 13 14 15 16

STAFF

Sloan Kettering Institute Members 149 143 140 140 131 Hospital Attending Staff 876 935 995 1,033 1,091 Registered Nurses 2,133 2,221 2,373 2,605 2,864 Administrative & Support Staff 9,281 9,707 10,223 10,965 11,638 Total Staff* 12,402 12,975 13,699 14,711 15,697 Volunteers 1,018 1,004 902 967 943

EDUCATION

Residents and Clinical Fellows: Positions 445 464 465 464 468 Residents and Clinical Fellows: Annual Total 1,682 1,691 1,674 1,723 1,734 Research Fellows 320 323 351 355 344 Research Scholars 124 133 110 98 92 Research Associates 89 91 95 110 112 Graduate Research Assistants 39 41 47 47 43 PhD Candidates 222 227 239 265 292 MD/PhD Candidates 21 19 18 20 26 Registrants in CME Programs 3,968 3,681 5,614 3,581 4,724 Laboratory Medicine Students 8 9 9 18 20 Medical Observers 566 630 579 574 563 Medical Students 431 392 505 548 569 Nursing Students 178 179 257 312 351 Social Work Students 6 7 7 4 8 Radiation Oncology Technology Students 13 15 15 15 12 Physical Therapy Students 7 2 6 5 5 Occupational Therapy Students 4 2 3 2 2

*In 2016, 27 staff members held appointments in both the Institute and the Hospital.

57. INNOVATION

FINANCIAL SUMMARY

2016 TOTAL OPERATING REVENUES 2016 TOTAL OPERATING EXPENSES $3,980,362 $3,802,192

$2,137,409 Compensation and Fringe Benefits

$3,094,461 Patient Care Revenue

$425,624 $1,311,764 Grants, Contracts, and Purchased Supplies Royalties and Services

$248,095 $263,964 Contributions and Pledge Depreciation and Payments Amortization

$212,182 $89,055 Other Income Other Expenses

58. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

12 13 14 15 16

OPERATING REVENUES (in thousands) Patient Care Revenue $2,201,941 $2,367,731 $2,560,457 $2,809,813 $3,094,461 Grants and Contracts 185,160 202,061 229,562 234,402 257,893 Contributions 128,253 138,343 168,797 137,538 161,245 Net Assets Released from Restrictions — Pledge Payments 86,820 79,199 103,112 129,528 86,850 Royalty Income 78,350 94,058 162,710 197,885 167,731 Other Income 51,167 57,150 62,643 66,032 75,203 Unrestricted Investment Return Allocated to Operations 75,877 82,028 87,917 90,648 136,979 Transfer of Board-Designated Annual Royalty Annuitization 51,709 57,495 15,885 9,639 0

Total Operating Revenues $2,859,277 $3,078,065 $3,391,083 $3,675,485 $3,980,362

OPERATING EXPENSES Compensation and Fringe Benefits $1,582,212 $1,689,501 $1,782,477 $1,987,388 $2,137,409 Purchased Supplies and Services 879,219 924,691 1,062,603 1,172,467 1,311,764 Provision for Bad Debts and Assessments 17,541 19,969 35,859 64,194 40,331 Depreciation and Amortization 210,810 210,373 217,342 232,866 263,964 Interest Expense 54,894 55,039 50,147 49,401 48,724

Total Operating Expenses $2,744,676 $2,899,573 $3,148,428 $3,506,316 $3,802,192

INCOME FROM OPERATIONS $114,601 $178,492 $242,655 $169,169 $178,170

PHILANTHROPIC REVENUE $231,159 $380,500 $376,533 $276,747 $317,270

CAPITAL SPENDING $258,613 $315,282 $473,859 $710,873 $634,134

BALANCE SHEET SUMMARY Assets $7,795,606 $8,481,418 $8,963,268 $9,592,021 $9,891,492 Liabilities 3,562,546 3,337,444 3,596,860 4,058,058 4,160,515

Net Assets $4,233,060 $5,143,974 $5,366,408 $5,533,963 $5,730,977

59. INNOVATION

BOARDS OF OVERSEERS AND MANAGERS as of March 31, 2017

DOUGLAS A. WARNER III JAMES D. ROBINSON III Chair Honorary Chair

MARIE-JOSÉE KRAVIS LOUIS V. GERSTNER, JR. Vice Chair of Boards Honorary Chair of the Board, Chair, Board of Managers, Sloan Kettering Institute Sloan Kettering Institute

SCOTT M. STUART RICHARD I. BEATTIE Vice Chair of Boards Honorary Chair of the Board, Chair, Board of Managers, Memorial Hospital Memorial Hospital

CLIFTON S. ROBBINS NORMAN C. SELBY CRAIG B. THOMPSON, MD Treasurer Secretary President and Chief Executive Officer

Dominic Barton Richard N. Foster, PhD James G. Niven William C. Steere, Jr. Richard I. Beattie Stephen Friedman Hutham S. Olayan John R. Strangfeld Aneel Bhusri Ellen V. Futter Bruce C. Ratner Scott M. Stuart Mrs. Edwin M. Burke Philip H. Geier, Jr. Clifton S. Robbins Craig B. Thompson, MD Mrs. John J. Byrne Louis V. Gerstner, Jr. Alexander T. Robertson Lucy R. Waletzky, MD Mrs. Joseph A. Califano, Jr. Jonathan N. Grayer James D. Robinson III Douglas A. Warner III Ian M. Cook William B. Harrison, Jr. Virginia M. Rometty Peter A. Weinberg Stanley F. Druckenmiller Benjamin W. Heineman, Jr. David M. Rubenstein Jon Winkelried Anthony B. Evnin, PhD David H. Koch Lewis A. Sanders Deborah C. Wright Roger W. Ferguson, Jr. Marie-Josée Kravis Norman C. Selby Jeff Zucker Henry A. Fernandez Donald B. Marron Stephen C. Sherrill Mortimer B. Zuckerman Steve Forbes Kathryn Martin + Lavinia Branca Snyder William E. Ford Jamie C. Nicholls Peter J. Solomon

+ ex officio

BOARD OF OVERSEERS EMERITI Peter O. Crisp Elizabeth J. McCormack, PhD Richard M. Furlaud Benjamin M. Rosen James W. Kinnear Fayez S. Sarofim Paul A. Marks, MD Mrs. Arnold Schwartz

BOARD OF SCIENTIFIC CONSULTANTS Frederick R. Applebaum, MD James R. Downing, MD Caryn Lerman, PhD James E. Rothman, PhD Richard Axel, MD Levi A. Garraway, MD, PhD Arthur Levinson, PhD William R. Sellers, MD Philip A. Cole, MD, PhD Maura L. Gillison, MD, PhD Richard Lifton, MD, PhD Gregory L. Verdine, PhD Nancy E. Davidson, MD Joseph L. Goldstein, MD Paul Nurse, PhD Ralph Weissleder, MD, PhD Titia de Lange, PhD Gregory Hannon, PhD Stanley R. Riddell, MD Irving L. Weissman, MD

60. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

LEADERSHIP MEMORIAL SLOAN KETTERING CANCER CENTER

as of March 31, 2017

CRAIG B. THOMPSON, MD KATHRYN MARTIN President and Chief Operating Officer Chief Executive Officer

JOSÉ BASELGA, MD, PhD JOAN MASSAGUÉ, PhD Physician-in-Chief and Director, Sloan Kettering Institute Chief Medical Officer, Memorial Hospital

ELIZABETH N. MCCORMICK, LARRY NORTON, MD KENT SEPKOWITZ, MD MURRAY F. BRENNAN, MD MSN, RN, CENP Deputy Physician-in-Chief, Breast Deputy Physician-in-Chief, Quality Vice President, International Senior Vice President and Chief Cancer Programs and Medical and Safety Programs and Director, Nursing Officer Director, Evelyn H. Lauder Breast International Center Center PETER STETSON, MD, MA RICHARD R. BARAKAT, MD Deputy Physician-in-Chief and Deputy Physician-in-Chief, PAUL SABBATINI, MD Chief Health Informatics Officer Regional Care Network and Deputy Physician-in-Chief, Clinical MSK Cancer Alliance Research

KERRY BESSEY JAMES T. HARDEN EDWARD J. MAHONEY WENDY PERCHICK Senior Vice President and Senior Vice President, Senior Vice President, Senior Vice President, Chief Human Resources Officer Strategic Partnerships Facilities Management and Strategic Planning and Innovation Construction MARGARET M. BURKE ELIZABETH A. HERBERT PATRICIA C. SKARULIS Senior Vice President, Senior Vice President, CYNTHIA MCCOLLUM Senior Vice President and Ambulatory Care and Hospital Hospital Administration Senior Vice President, Chief Information Officer Operations Hospital Administration JASON KLEIN CAROL A. SLATTERY ERIC COTTINGTON, PhD Senior Vice President and ANNE MCSWEENEY Vice President, Senior Vice President, Research Chief Investment Officer Special Advisor to the President, Sloan Kettering Institute and Technology Management Development Administration RUTH LANDE NED GROVES Senior Vice President, Patient AVICE A. MEEHAN MARK SVENNINGSON Executive Vice President and Revenues Senior Vice President and Senior Vice President, Hospital Administrator Chief Communications Officer Finance and Controller CAROLYN B. LEVINE, ESQ. MICHAEL P. GUTNICK Deputy General Counsel and RICHARD K. NAUM EDWIN TALIAFERRO Executive Vice President and Corporate Secretary Senior Vice President, Development Vice President, Internal Audit Chief Financial Officer and Compliance and JORGE LOPEZ, JR., ESQ. PAUL NELSON Chief Compliance Officer Executive Vice President and Senior Vice President, General Counsel Financial Planning

PAUL A. MARKS, MD President Emeritus

61. INNOVATION

LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES MEMORIAL SLOAN KETTERING CANCER CENTER as of March 31, 2017

LOUIS V. GERSTNER, JR. CRAIG B. THOMPSON, MD Chairman of the Board President

JOAN MASSAGUÉ, PhD KENNETH J. MARIANS, PhD LINDA D. BURNLEY Provost Dean Associate Dean

KATHRYN MARTIN MARK SVENNINGSON CAROLYN B. LEVINE, ESQ. Treasurer Assistant Treasurer Secretary

TRUSTEES Richard I. Beattie Marie-Josée Kravis Ellen V. Futter Craig B. Thompson, MD Louis V. Gerstner, Jr. Douglas A. Warner III David H. Koch

SLOAN KETTERING DIVISION WEILL CORNELL GRADUATE SCHOOL OF MEDICAL SCIENCES as of March 31, 2017

JOAN MASSAGUÉ, PhD KENNETH J. MARIANS, PhD Director Director, Graduate Studies

GRADUATE PROGRAM CO-CHAIRS

NIKOLA P. PAVLETICH, PhD DAVID A. SCHEINBERG, Biochemistry and MD, PhD Structural Biology Unit Pharmacology Unit

ANDREW KOFF, PhD ALEXANDER Y. RUDENSKY, Molecular Biology Unit PhD Immunology and Microbial MARILYN D. RESH, PhD Pathogenesis Unit Cell and Developmental Biology Unit

62. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING CONCLUDES RECORD-SETTING RUN

After 15 years of unprecedented achievement, the Campaign for Memorial Sloan Kettering officially came to a close on December 31, 2016, having raised a total of $4.2 billion in gifts and pledges — and topping its final $3.5 billion goal by some $700 million. The Campaign, which began recording gifts in January 2001, was MSK’s first major fundraising drive since the 1980s.

Originally conceived as a five-year effort, the Campaign was extended twice and its goal more than tripled. Gifts to the Campaign have helped ensure MSK’s position at the forefront of today’s ongoing transformation in cancer research and treatment. Clockwise from top: Douglas A. Warner III, Louis V. Gerstner, Jr., Craig B. Thompson, a Cycle for Survival event Leading the historic fundraising effort for its entire in San Francisco. run were co-chairs Douglas A. Warner III and Louis V. Gerstner, Jr. In addition to working directly with donors At the same time, MSK introduced a range of — while also making their own generous contributions — programs designed to encourage donor support at they established a tone for the Campaign that reflected every level. For example, online giving has emerged the institution’s highest aspirations. Together with as an important vehicle for contributions in the years Craig Thompson and their colleagues on the MSK Board, since MSK received its first such gift in 2004. Online the co-chairs worked to ensure that the Campaign giving achieved a compound growth rate of 29 percent not only generated record gift totals but also that the between 2004 and 2016. contributions were directed to meeting MSK’s top priorities. Of particular note, MSK’s premier athletic event, Cycle for Survival, has grown steadily as a source of In all, Memorial Sloan Kettering received 13.7 million philanthropic support while also serving to expand gifts during the course of the Campaign — an extraordinary and diversify MSK’s donor population. To date, more outpouring of generosity from benefactors whose than 560,000 donors from 102 countries have made contributions both large and small were inspired by the contributions in support of the event. In 2016, Cycle for pioneering work being done by MSK’s physicians and Survival celebrated its tenth anniversary by raising scientists. This support, in turn, provided the means $30 million from events held in 16 cities across the US. to strengthen and expand initiatives in every area of Memorial Sloan Kettering’s mission. Under the direction of Anne M. McSweeney, Special Advisor to the President for Development, and Senior Exemplifying the sense of commitment shown by Vice President Richard K. Naum, MSK built one of the MSK’s benefactors were the farsighted men and nation’s most productive and highly efficient fundraising women who set the pace for giving to the Campaign. operations during the course of the Campaign. As a Contributions of $1 million and above helped drive result, MSK has in place solid foundations for the long- MSK’s entire fundraising effort, accounting for term fundraising success that will help fuel the ongoing 65 percent of the Campaign’s total achievement. revolution in cancer medicine.

63. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

$200,000,000 AND ABOVE $20,000,000 — $24,999,999 $5,000,000 — $9,999,999 Richard Serra and Clara David H. Koch Anonymous Anonymous Weyergraf-Serra The Society of MSK Band of Parents Foundation The Peter Jay Sharp The Thompson Family Robert and John Bendheim Foundation Foundation The Leon Black Family Mr. and Mrs. Richard Siegal $100,000,000 — Foundation, Inc. Estate of Margaret McCormack $199,999,999 The Carson Family Charitable Sokol The Estate of Geoffrey Beene Trust The William and Lynda Steere Mr. and Mrs. William H. $10,000,000 — $19,999,999 The Steven A. and Alexandra Foundation Goodwin, Jr., and the Anonymous M. Cohen Foundation, Inc. Swim Across America, Inc. Commonwealth Foundation Bristol-Myers Squibb Company Ian and Patricia Cook The Three Little Pigs for Cancer Research Trust of Burton Abrams Trust of Richard J. Eisemann Foundation Henry and Marie-Josée Kravis The Kristen Ann Carr Fund Mr. and Mrs. Philip H. Geier, Jr. UBS The Starr Foundation Mr. and Mrs. Raymond T. Dalio Family of Charles Hallac John L. Vogelstein Mortimer B. Zuckerman The Stephen and Barbara Estate of Sherlock Hibbs Sue and Edgar Wachenheim III Friedman Foundation ICAP The Weinberg Family Alan and Sandra Gerry The Jewish Communal Fund Foundations The Arnold and Arlene Dr. and Mrs. Min-Hwan Kao Michael A. and Zena Wiener $50,000,000 — $99,999,999 Goldstein Family Foundation F. M. Kirby Foundation, Inc. Stanley F. and Fiona Trust of Steven A. Greenberg The Robert J. Kleberg, Jr., and Druckenmiller The Donald B. and Catherine C. Helen C. Kleberg Foundation The Leonard and Evelyn Marron Foundation Trust of L. H. P. Klotz $2,500,000 — $4,999,999 Lauder Foundation The Robert and Kate Niehaus John W. Kluge Anonymous Virginia and D. K. Ludwig Fund Foundation Trust of Evelyn Lauder Mr. and Mrs. Bruce Adam for Cancer Research Mr. and Mrs. Milton Petrie The Lebensfeld Foundation Alex’s Lemonade Stand Robertson Foundation Laurance S. Rockefeller Estate of Tse Kyung Lee Foundation Laurance S. Rockefeller Fund The Leon Lowenstein The Allbritton Foundation Donna and Benjamin Rosen Foundation, Inc., and Robert Bethany Allen Allan H. Selig and John Bendheim Stephen and Madeline $25,000,000 — $49,999,999 Robert F. X. Sillerman and The Lustgarten Foundation for Anbinder The Atlantic Philanthropies Laura Baudo Sillerman Pancreatic Research John M. Angelo and Judy Hart The Elmer and Mamdouha through their Tomorrow Martin S. and Sheila Major and Angelo Bobst Foundation Foundation Family The Laura and John Arnold The Breast Cancer Research The Simons Foundation Melanoma Research Alliance Foundation Foundation The Society Boutique — Estate of Samuel U. Mitchell Estate of Eleanor Backer Jack and Dorothy Byrne MSK Thrift Shop Jamie Nicholls and Fran Biondi The Arthur & Rochelle Belfer Foundation The Society of MSK Special Charitable Trust Foundation The Louis V. Gerstner, Jr. Projects Committee Peserga International Estate of Mary Ann Benjamin Foundation, Inc. Stand Up To Cancer Foundation Estate of Lillian R. Berkman The Sidney Kimmel Stop & Shop Supermarket Frederick Henry Prince Mr. and Mrs. Melvin R. Berlin Foundation Company, Inc. Memorial Fund Family Parker Institute for Cancer Mr. and Mrs. Douglas A. Bruce C. Ratner The James E. and Diane W. Immunotherapy Warner III Mr. and Mrs. John S. Reed Burke Foundation, Inc. Prostate Cancer Foundation Estate of Kathryn D. Wriston The Robbins Family Burroughs Wellcome Fund David M. Rubenstein Foundation Estate of Nizza Burstyn The Tow Foundation Dorothy Rose and Dr. Milton Mrs. D. Wayne Calloway Rose Iris and B. Gerald Cantor Damon Runyon Cancer Foundation Research Foundation Estate of Marion B. Carstairs Lewis A. Sanders James D. Carter Estate of Joseph J. Santry Estate of Franklin Chenenky Nassef Sawiris

64. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Pei-Yuan Chia and the Chia The G. Harold & Leila Mathers The V Foundation for Cancer The Y. C. Ho/Helen and Family Foundation Foundation Research Michael Chiang Foundation Charles Payson Coleman Estate of Charles J. Mauro Trust of Bessie Weintraub Trust of Paul H. Chook Crimson Lion / Lavine Family The Abby R. Mauzé Charitable Trust of Charles P. Ciaffone Foundation Trust Trust of George Clegg The Irma L. and Abram S. Croll Estate of Florence Miner Simon & Eve Colin Charitable Trust Gloria Miner $1,000,000 — $2,499,999 Foundation, Inc. The Decathlon The Naddisy Foundation Estate of Marguerite Abrams The Comer Science and The Doris Duke Charitable The New York Community Mr. and Mrs. Andrew B. Education Foundation Foundation Trust Abramson Estate of Gloria S. Confort The Mitzi and Warren The Samuel I. Newhouse Mr. and Mrs. Frederick R. Adler The Connecticut Sports Eisenberg Foundation / The Foundation Mr. and Mrs. Fred M. Alger III Foundation Susan and Leonard Feinstein Stavros S. Niarchos Foundation Allen & Company, Inc. Cookies for Kids’ Cancer Foundation Nonna’s Garden Foundation Estate of Billie H. Allen Trust of James J. Corbalis, Jr. Anthony B. and Judith W. Ronald O. Perelman Elisabeth and Philip Allen Carlos A. Cordeiro Foundation Evnin Estate of Catherine R. Price The Rita Allen Foundation Sharon Levine Corzine Farmer Family Foundation Laura and Christopher A. Alliance for Cancer Gene Trust of Caroline S. Coulton Estate of Elizabeth M. Pucillo Therapy The Countess Moira Frelinghuysen Mrs. Katharine J. Rayner Anonymous Foundation Estate of Jeanette R. Fulham The Jim and Linda Robinson Estate of Roone P. Arledge Mr. and Mrs. Peter O. Crisp Goldman Sachs & Company Foundation Arms Wide Open Childhood Cure Breast Cancer Estate of Francis Gonzalez Jack Rudin Cancer Foundation Foundation, Inc. The Gray Foundation - Basser The Louis & Rachel Rudin The Award of Courage Estate of Helen M. Curry Initiative Foundation Corporation Trust of Margaret E. Dahm Mr. and Mrs. Jonathan N. The May & Samuel Rudin Roger and Lori Bahnik John and Georgia DallePezze Grayer Family Foundation Estate of Eileen W. Bamberger Dennis D. Dammerman Hazen Polsky Foundation, Inc. Estate of Marilyn L. Schaefer The Batishwa Fellowship The Dana Foundation William Randolph Hearst Estate of Grace A. Shapro Trust of Edgar D. Baumgartner Mr. and Mrs. Marvin H. Foundations Dr. David E. and Beth Kobliner Estate of Leola E. Bell Davidson Mr. and Mrs. Benjamin W. Shaw Mr. and Mrs. Daniel C. Benton Trust of Myra Davis Heineman, Jr. Mr. and Mrs. H. Virgil Sherrill Estate of Irma Berg Estate of Bernard S. Davison The Charles and Marjorie The Joachim Silbermann Allen and Joan Bildner Christina and Emmanuel Di Holloway Foundation, Inc. Family The Anita and Leonard Boxer Donna Estate of Irma A. Howard Paul E. Singer Family Foundation Estate of Charles E. Dillman William Lawrence & Blanche Joan and Joel Smilow Breast Cancer Alliance, Inc. James and Judith K. Dimon Hughes Foundation Susan and Peter Solomon Mr. and Mrs. Viatcheslav I. Gloria DiPietro-Cooper Humans of New York Family Foundation Brecht Trust of James Douglas W. M. Keck Foundation The Sontag Foundation Peter and Linda Bren Michael Douglas and Catherine Estate of Martin C. Kessler Sportsmen for Charity The Andrea and Charles Zeta-Jones Kids Walk for Kids with Cancer Trust of Marie Stephenson Bronfman Philanthropies, Trust of Nancy K. Dunn Susan G. Komen for the Cure George Strawbridge, Jr. Inc. Trust of Phyllis K. Dunn Myra Nelson Larrison The Margaret Dorrance Estate of Helen Brown The Ellison Medical Livestrong Foundation Strawbridge Foundation of Trust of Emil A. Buelens Foundation The Lymphoma Foundation Pennsylvania I Tory Burch The Emerald Foundation Trust of Philip R. Mallory Mr. and Mrs. Scott Stuart Estate of Diane B. Burkhart Mr. and Mrs. Israel Englander The Maloris Foundation The Joseph and Arlene Taub The Burnett Foundation Entertainment Industry Trust of Estelle A. Manning Foundation Mr. and Mrs. Donald G. Calder Foundation The T. J. Martell Foundation Margaretta J. Taylor Cancer Research Institute Mr. and Mrs. David Epstein for Leukemia, Cancer and Estate of Richmond E. Robert B. Catell Equinox Holdings, Inc. AIDS Research Thompson John and Michael Chandris Estate of Selma Ettenberg Trust of Jane Toplitt The Laura Chang and Arnold The Eunice Foundation TOSA Foundation Chavkin Charitable Fund Edward P. Evans Foundation

65. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Estate of Harry Fagen The Marion and Louis Gerald Leigh Charitable Trust The New York Yankees Trust of Harold Farrington Grossman Foundation Estate of Wilhelmina LeJeune Foundation Fayez Sarofim & Co. Mr. and Mrs. Robert Grossman The Lerner Foundation George L. Ohrstrom, Jr. The John K. Figge Family Trust of Helen Guerin Estate of Ada Leventhal Foundation Estate of Barbara D. Finberg Kate Medina Guthart and Leo Estate of Harold F. Levinson The Olayan Group First Quality Enterprises, Inc. A. Guthart Leon Levy Foundation The Ovarian Cancer Research The Jerome and Anne C. Fisher Hackers for Hope The LisaBeth Foundation Fund Charitable Foundation Mr. and Mrs. James J. Hagan The Litwin Foundation Pancreatic Cancer Action Flight Attendant Medical Estate of Joseph M. Hand Harry J. Lloyd Charitable Network Research Institute Mr. and Mrs. John J. Hannan Trust Francine Parnes The Stephanie and Lawrence Estate of Margaret H. Hanson Carol and Michael Lowenstein Pediatric Cancer Foundation Flinn, Jr. Charitable Trust Stephen P. Hanson Robert S. Ludwig and Gwenyth Estate of Frederick Pelda The Raymond and Maria Floyd Jamie and Jeffrey Harris E. Rankin John and Francie Pepper Family Foundation Gladys and Roland Harriman Lymphoma Research Trust of Elizabeth L. Perkins Estate of Harry N. Forman Foundation Foundation Perry Capital LLC Lorraine Friedman Hassenfeld Family Mr. and Mrs. J. Randall Pfizer Inc. Trust of Oscar H. Friedman The Heckscher Foundation for MacDonald Estate of Jeanne Poli Friezo Family Foundation Children Mr. and Mrs. Joel Mallah Bernard Posner Trust of Mary Frohsinn Estate of Marie B. Hilliard The Lois H. Mann Charitable Mrs. Jenice Pulver Fund for Ophthalmic Estate of Brian W. Holman Foundation Sara and Iser Rabinovitz Knowledge Estate of Harriet Huber Margaux’s Miracle Foundation RBC Capital Markets Estate of Frank H. Gabriel The Howard Hughes Medical Mrs. Joseph L. Martino Revlon Gabrielle’s Angel Foundation Institute Mrs. William L. Matheson Charles H. Revson Foundation Sara Gadd Estate of Dorris J. Hutchison Nancy and Paul McCartney Trust of Allan J. Riley Estate of Thomas Gardiner Leslie Hutchison and Virginia Mr. and Mrs. Thomas E. RJR Oncodermatology Fund Trust of Virginia L. Garrison Shaw McInerney Estate of Edith Roberts The Gateway for Cancer Hyundai Hope on Wheels Estate of Donald G. McKeon Estate of Josephine T. Research IBM Corporation Estate of Myra L. McKolic Robertson Trust of Florence K. Geffen Inspire 2 Live Foundation Merrill Lynch & Co. Estate of Anne Morales The Lawrence M. Gelb Barbara and Tom Israel Foundation, Inc. Rodgers Foundation, Inc. Trust of Harry C. Jaecker, Jr. Fred and Marie-Noelle Meyer Mary Jo and Brian Rogers Richard L. Gelb The Rona Jaffe Foundation Estate of Wilma S. Mills The Felix and Elizabeth Genentech Estate of Clarence W. Johnson Jim and Mary Jane Milton Rohatyn Foundation General Electric Company Estate of Wilda Johnson Julie and Edward J. Minskoff The Laura Rosenberg Eileen Genet Fund for Ovarian J. P. Morgan Chase Estate of Robert C. Mitchell Foundation, Inc. Cancer Research and The JPB Foundation Trust of Douglas C. Mohl Estate of Lillian E. Prevention Trust of Marion Kahn The Ambrose Monell Rosenmerkel Trust of Josephine A. Gilmore Katzman Family Foundation Foundation Juliet Rosenthal Foundation Estate of Thelma Gish Brian & Joelle Kelly Family Tom and Janet Montag The Peter M. Sacerdote GIST Cancer Research Fund Foundation Estate of Warren A. Montel Foundation Estate of Anna H. Gleason The Brian Kennedy Trust Morgan Stanley The Raymond & Beverly Miriam and Alan Goldberg Estate of Mary B. Ketcham The William T. Morris Sackler Fund for the Arts and The Joyce & Irving Goldman Layla and Ed Khalily Foundation Sciences Family Foundation Estate of John W. Knox Trust of Anna V. Muller Estate of Margaret W. Schafer The Horace W. Goldsmith Mr. and Mrs. Matania Kochavi Estate of Elaine Muller The Richard H. Schneider Foundation Estate of Rosemarie Krulish Mushett Family Foundation, Family—Tami, Brady and Golfers Against Cancer The Thomas G. Labrecque Inc. Casey Schneider Foundation Foundation Trust of Saul Nathonsohn Estate of Catherine M. The Gordon Fund Trust of Grace Fay Lamb The National Brain Tumor Schooley Estate of Andrew S. Gordon Estate of Emma Landau Society The Beatrice & Samuel A. Trust of Jane H. Gordon Philippe Laub Needles’ Family Charitable Seaver Foundation Grass Family Foundation Lebara Foundation Lead Trust Mr. and Mrs. Norman C. Selby

66. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

The Shen Family Foundation Trust of Virginia and Edward The Bie Family Foundation The Elaine Terner Cooper Trust of Henry H. Shepard Van Dalson Estate of Dan Biele Foundation Trust of William and Isabelle Vanguard Charitable Jane and Bill Bird Trust of Faye Copeland Sherlock Endowment Fund Estate of Philip Bisaccio Estate of Howard Corlies Mr. and Mrs. Stephen C. Estate of William N. Vaughan Trust of Susan E. Black Estate of Leonard Corso Sherrill Trust of Edward W. Vollintine Mr. and Mrs. John N. Frederic R. Coudert Alfred J. and Stephanie Trust of Paul H. Volpe Blackman, Jr. Foundation Shuman through the Lucy R. Waletzky, MD Betty, James, and Thomas Chandler Cox Foundation Windmill Lane Foundation Joan and Sanford I. Weill Blake (The Thomas Blake, Sr. Estate of Helen M. Cramer Mr. and Mrs. Herbert J. Siegel Louis and Jane Weinstock Memorial Fund) CURE Childhood Cancer M. Steven and S. David The Lillian S. Wells The Blue Dot Foundation CureSearch for Children’s Silbermann Foundation, Inc. Antoinette E. & Herman Cancer The Rosanne H. Silbermann Mr. and Mrs. Clay T. Whitehead Boehm Foundation Mr. and Mrs. Rafic Dahan Foundation Judy and Fred Wilpon Family Trust of Ethelvida Boehme Estate of Thomas R. Daly Mary Ann and Arthur M. Foundation, Inc. Estate of William Boehme Davis Charitable Foundation Siskind through the Siskind Estate of Carolyn H. Wilson Mr. and Mrs. David Boies Estate of Sandra Newman Family Sarcoma Fund Winterburn Foundation Estate of Marcel S. Bollag Dawson The Skirball Foundation Diana S. Wister Trust of Frederick W. The Thompson Dean Family Estate of Ann Smith The Meryl and Charles Witmer Bonacker, Jr. Foundation Trust of William Kirkland Charitable Foundation The Bondi Foundation Estate of Carol T. Decker Smith The Wolfensohn Family Estate of Adele Bozio The DeGroot Family Trust of Emily V. Smyth Foundation Trust of Nancy J. Bradford Foundation Trust of Clemance and Edwin Mr. and Mrs. Robert Wright Terri Brodeur Breast Cancer Annette and Oscar de la Renta Snyder Zev’s Fund Inc. Foundation Frederick A. DeLuca Ira Sohn Conference Ziff Brothers Investment, LLC Trust of Dorothy Fielder Brown Foundation Foundation, Inc. Ronald Zung The Honorable Tina Brozman Dempster Charitable Trust St. Baldrick’s Foundation Foundation Deutsche Bank Securities Inc. John R. & Inge P. Stafford Mrs. Edwin M. Burke Elizabeth K. Dollard Foundation Janet Burros Memorial Charitable Trust Bonnie and Steven E. Stern $500,000 — $999,999 Foundation Estate of Ruth Drazen Estate of Stanley R. Stones Agilent Technologies, Inc. Hilary and Joseph A. Califano, The Walter S. and Lucienne B. Mr. and Mrs. David K. Storrs AKTIV Foundation Jr. Driskill Foundation Mr. and Mrs. Paul A. Street American Brain Tumor The Cancer Research Estate of Louis Duenweg The Sussman Family Fund Association Foundation of America Mr. and Mrs. Barclay Ehrler Trust of M. Allen Swift The American Italian Cancer The Richard E. Capri Trust of Virginia J. Faber Tang Family Foundation Foundation Foundation on behalf of the Arthur Falcone Tarnopol Family Foundation American Skin Association Wolf Family Estate of Katie Fasal Terry Fox Run for Cancer Estate of Hugo Andriesse Estate of Richard B. Carman Estate of Beatrice Feinstein Research (NYC) Anonymous Mr. and Mrs. Kenneth Carmel Paul Felzen Trust of Irving Tirkfield Roland Arthur Estate of Wesley S. Carnrick The Fibrolamellar Cancer Estate of Lillian Tomek Aventis Pharmaceuticals, Inc. The Tina and Richard V. Foundation The Beth C. Tortolani Gail L. Baird Family Carolan Foundation Estate of Alice H. Ficht Foundation Foundation James & Patricia Cayne Trust of Alice D. Fiedler Dom and Tia Tran Mr. and Mrs. Robert C. Baker Charitable Trust Trust of Marie Finch Anthony and Carole Trapani Family Foundation Trust of Betty R. Ciaffone The Grace J. Fippinger The Trump Group Trust of Barbara G. Bargar Citigroup Foundation, Inc. Tudor Investment Corporation Estate of Doris A. Baumann The Julie and Frank Cohen Estate of Susan L. Fischer Daniel P. and Grace I. Tully Richard I. Beattie Foundation The Michael J. Fox Foundation Foundation The Arnold and Mabel Estate of Harry J. Colish Trust of Ira S. French Mr. and Mrs. Thomas Tuttle Beckman Foundation The Julien Collot Foundation, Trust of Dr. Benjamin T. Uniting Against Lung Cancer Trust of William T. Benitt Inc. Friedman Universal Network Television The Besen Family Constant Convocation Center Trust of Edith West Friedmann

67. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

The Anna Fuller Fund Invest for Children, Max Cure Foundation Estate of Marion M. Pincus Estate of Maud Gallagher a Foundation of Mr. and Mrs. Louis V. Mazzella Plastic Surgery Foundation Estate of Joseph G. Gaumont Investindustrial Estate of William J. McCann Josephine K. Poling Estate of Selma Geller Mrs. H. Anthony Ittleson Trust of John C. McCormick Polo Ralph Lauren Corporation Joe Gellert Johnson & Johnson Mr. and Mrs. Thomas R. Ruth Porat and Anthony Estate of Lillian B. George Estate of Al Jolson McCullough Paduano The Gerber Foundation Estate of Horace A. Jones The James S. McDonnell Estate of Gerald E. Proctor The Aaron and Betty Gilman Stephanie and Ken Karl Foundation Project A.L.S. Family Foundation Trust of Norman Katz Estate of Ralph Melson Margot Rosenberg Pulitzer Estate of William J. Glasgow Fritz and Adelaide Kauffmann The Mesothelioma Applied Foundation Estate of Robert E. Gleason Foundation Research Foundation PVH Corp. Mr. and Mrs. Robert S. Mr. and Mrs. Robert B. Kay Metlife Foundation The Mitchell P. Rales Family Goldberg Pamela and Dwaine Kimmet The Merck Company Foundation Alfred G. & Hope P. Goldstein Kinetics Foundation Foundation Recanati Foundation Fund Estate of Joan E. Kinley Estate of Ruth Vitow Messias John Bradbury Reed Estate of Helen M. Golen Estate of Hazel V. Knapp Trust of Russell A. Meyer Trust of Irene Dorothy Reel Mr. and Mrs. Sidney Goodfriend Estate of Ruth Koch Peter Michael Foundation Estate of Muriel G. Reich David J. Grais and Lisa A. The Koodish Family Charitable The Milbank Foundation for James N. Rentas 5K Run/Walk Cutler Trust Rehabilitation Estate of Agnes Rezler Mr. and Mrs. Alan I. Greene The Kronthal Family The Norman M. Morris Trust of Argyll C. Rice Trust of Phyllis A. Greene The Jacob & Valeria Langeloth Foundation Estate of Richard A. Riecker Trust of Richard M. Greifer Foundation Trust of Paula Moss Louise and Frank Ring Estate of Edythe Griffinger Trust of Charles T. Larus Mr. and Mrs. Charles H. Mott The Andréa Rizzo Dance Peter M. Guggenheimer Estate of Owen Laster Movember Therapy Fund The Marc Haas Foundation Eugene and Elizabeth Lavin Multiple Myeloma Research Rock Out for the Cure Mr. and Mrs. William W. Lazard Capital Markets Foundation Drs. Helena and David Rodbard Haerther, Jr. Estate of Anne Leventon Muscular Dystrophy Alexander J. Roepers Estate of Ethel V. Haldeman Mr. and Mrs. Allan L. Levey Association Shafi Roepers Evelyn A. J. Hall Charitable Dr. Nancy Alpern Levin Mustaches for Kids Trust of William C. Rogers Trust Fran and Ralph Levine National Childhood Cancer Mr. and Mrs. Stephen J. Mr. and Mrs. Stephen L. Life Raft Group Foundation Rosenthal Hammerman Estate of Lillian Light Carole and Raymond Neag The Arthur Ross Estate of Olga V. Hargis Trust of Catherine M. Lincoln S. Arthur and Dorothy Neufeld Foundation, Inc. Mr. and Mrs. William B. Estate of Leah W. Linn Foundation Helena Rubinstein Foundation Harrison, Jr. Live4Life Foundation News Corporation Amanda and David Russekoff Jane Hope Hastings Trust of Martin C. and Occidental Petroleum Trust of Edward G. Ryder Philanthropic Trust Margaret V. Lohsen Corporation Moise Safra Family Estate of Judith B. Helfant Trust of Louis J. Lombardi Trust of Melba M. O’Connell Dr. Nathan E. Saint-Amand Trust of Richard V. Henry, Jr. Mr. and Mrs. Edward Lundy The Sylvan and Ann Wendy and Neil Sandler Estate of Ruth H. Hewlett Lung Cancer Research Oestreicher Foundation Sarcoma Foundation Trust of Milan M. Holdorf Foundation Trust of Jo Anne H. Olmsted of America Trust of Benjamin Holmes LUNGevity Foundation E. Stanley O’Neal Henry Schein Cares Trust of Karla Homburger Estate of Evelyn P. Lyon William C. and Joyce C. O’Neil Foundation Hope Funds for Cancer Earle I. Mack Foundation Charitable Trust Estate of George W. Schneider Research Manhasset Women’s Coalition Estate of Beatrice P. K. Palestin III Estate of Claire Hughes- Against Breast Cancer Elsa U. Pardee Foundation Ira Schneider Memorial Cancer Glasgow Estate of Lucille Knowles Party City Corporation Foundation Estate of Jane Hunter Freedman Mann The Perelman Family Estate of Alana M. Schuster The Patricia M. Hynes and Roy March of Dimes Foundation Foundation The Seraph Foundation L. Reardon Foundation Estate of Dana Marin The Perkin Fund Evelyn R. Simmers Charitable Deanne and Arthur Indursky Estate of Anne Markowitz Estate of Philip W. Pfeifer Trust Trust of Anthony J. Masard Estate of Lucie Picard Suzanne Cohn Simon

68. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Barbara K. Snader Vital Projects Fund, Inc. Joyce Ashley Mr. and Mrs. Norman Estate of William E. Snee Walk the Walk America, Inc. Estate of Rose Ashton-Irvine Brownstein Beatrice Snyder Foundation The Warner Foundation, Inc. The David R. and Patricia D. Estate of Madalyn B. Bryant Lavinia Branca Snyder The Wasily Family Foundation Atkinson Foundation The Bugas Fund The Society of MSK Associates Estate of Ingeborg K. Watson Avon Foundation Estate of Lillian Burg Committee Trust of Thomas J. Watson, Jr. B*Cured Estate of Edith R. Burger Society of New York Workers’ Estate of Ruth C. Weismann Estate of William C. Bahn, Jr. Gilbert and Ildiko Butler Compensation Bar Mr. and Mrs. Harold S. The Banbury Fund Family Foundation, Inc. Association Wertheimer Estate of Iris Baranof Estate of Marian Butler Estate of Katherine R. WestRock Foundation Trust of Margaret D. Barber Cancer Support Services, Inc. Sonneman Trust of Reamer W. Wigle Estate of Florence Barrack The Paul Robert Carey Trust of Shirley J. Sontag Jacqueline and Robert Willens Estate of Marcia Batten Foundation Roy M. Speer Foundation The David and Ellen Williams Betsy L. Battle Mr. and Mrs. Michael Carr Spin4Survival Foundation Trust of Gertrude E. Beck Mark A. Castellano Mrs. Kay Stafford and the late Trust of Maria Wolter Estate of Grace Becker Estate of Georgia M. Catrini Senator Ronald B. Stafford Trust of Richard A. Yudkin Cheryl K. Beebe and James A. Trust of Ruth C. Celarek Trust of Barbara A. Stapleton Estate of Anna M. Zavatt Grimm Estate of Burdette G. Estate of Helen E. Steadman Estate of Ethel A. Bell Chamberlin Mr. and Mrs. Howard Stern Trust of Virginia Poole Trust of Cicely J. Chandler Trust of Charles M. Stevenson Benjamin Mr. and Mrs. Bernard T. Chauss The Mel Stottlemyre Myeloma $250,000 — $499,999 Corinne Berezuk and Michael Joan Chorney Foundation Trust of George Aaron Stieber Chris4Life Colon Cancer Trust of James Strobridge AbbVie Foundation Bergstein Family Foundation Foundation Mrs. Laure Sudreau-Rippe Accelerate Brain Cancer Cure Estate of Gertrude G. Bernstein Florence Chu, MD The Michael Sweig Foundation (ABC2) Foundation The Lisa E. Bilotti Foundation CIBC World Markets J. T. Tai & Co. Foundation Estate of John D. Adams, Jr. The Blackstone Charitable Corporation Ping Y. Tai Foundation Dr. Miriam and Sheldon G. Foundation The Clark Foundation James R. Tanenbaum and Adelson Medical Research James Blake Foundation Estate of Gerald Clements Elizabeth M. Scofield Foundation The Nancy and Robert S. Blank Estate of Dorothy L. Cobb The Edward N. & Della Adenoid Cystic Carcinoma Foundation Trust of Joan F. Cobb L. Thome Memorial Research Foundation Trust of Ronald M. Blau Estate of Frances B. Cohen Foundation, Bank of America, The Louis & Bessie Adler Estate of Ida Bloom Coins for Alzheimer’s Research N.A. Trustee Foundation Albert and Betty Bodian Trust The Craig D. Tifford Trust of Sebastian & Helen Estate of Marthe Bonneau Paul Jackson Coleman Foundation, Inc. Albrecht Trust of Lillian Borchardt Mr. and Mrs. John K. Colgate, TripAdvisor Charitable The Alliance Against ASPS The Louis L. Borick Foundation Jr. Foundation Foundation The Albert C. Bostwick Terry Collins Barbara Davies Troisi Trust of Eileen Alpert Foundation The Community Foundation Foundation Alzheimer’s Association Mr. and Mrs. Kevin A. for Northern Virginia – Thomas N. Tryforos American Asthma Foundation Bousquette Hanlon Family Fund Estate of Stanley F. Tucker American Health Assistance Trust of Alice M. Branch Estate of Robert I. Conley Turner Construction Company Foundation The Braver Foundation Cooley’s Anemia Foundation Twenty-First Century Fox, Inc. The American Ireland Fund Bridgemill Foundation Estate of Lillian Copperman The Tyler Foundation The Ametek Foundation, Inc. Estate of Paul P. Brieloff Estate of Leonard Cossack United Way of Tri-State Dorothy A. Anderson Bright Focus The Cowles Charitable Trust Trust of Ward M. Vanderpool Estate of Margaret B. Anderson The Brightwater Fund, Gloria Estate of Mary O. Craft The Vanneck-Bailey Anonymous Jarecki Estate of Edna W. Curl Foundation Estate of Mark J. Anton Trust of Marie H. Brock Filomen M. D’Agostino Variety – The Children’s Estate of Anita S. Appel Trust of Constantine Brown Foundation Corp. Charity Mr. and Mrs. Frank W. David A. and Merle L. Brown Estate of Rosetta Damilano Richard C. Vergobbi Appleton, Jr. Brownstein Hyatt Farber Trust of DeWitt S. Davidson Estate of Christine Villano Estate of Bente Arquin Schreck Guy and Sally Davidson

69. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Richard L. Davies Estate of Ralph R. Feigelson Mr. and Mrs. Eugene J. Glaser Estate of Dorothy M. Holder The Arthur Vining Davis The Feinstein Family Mr. and Mrs. Bradley Goldberg Estate of Martha Holloway Foundations Foundation Leslie H. Goldberg Mr. and Mrs. D. Gregory Estate of Frederick W. Davis The Isabel, Harold, and Gerry Trust of Marc S. Goldberg Horrigan Estate of Leonard Davis Feld Fund for Bereavement Corinne and Daniel Goldman Estate of Chester S. Howard Trust of Marion E. Dean Hilary Carla Feshbach Susan Wallack Goldstein Dina Hubell and the Labkon Deborah A. DeCotis Mrs. Frederick Fialkow Arthur A. Gosnell Family Estate of Lorraine J. Dehoog Estate of Selma Fine Estate of Barbara Grace Estate of Karen L. Hudson Trust of Carolyn B. Denney First Eagle Investment Estate of Felice M. Grad Hunter Douglas The De Rosa Foundation for Management Graff Diamonds Syde Hurdus Foundation, Inc. Colon Cancer Research Jeanne Donovan Fisher Graham Holdings Company IBM International Foundation and Prevention The Jodi Spiegel Fisher Cancer Granary Associates The Interpublic Group of The Desmoid Tumor Research Foundation The Grateful Foundation, Inc. Companies Foundation Aaron Fleischman and Lin Mr. and Mrs. Peter G. Grayson Bruce H. Jacobs Hester Diamond Foundation Lougheed Foundation Susan Zises Green Trust of Clyde H. Jacobs Mr. and Mrs. Lyman B. The Floren Family Foundation Estate of Eldridge A. Greenlee Harry A. Jacobs, Jr. Dickerson Fondazione Italiana Grinberg Family Foundation Janssen Pharmaceutical The Dickson Foundation For the Love of Life Virginia and Howard Products LP Estate of Evelyn Z. Diehl Steve Forbes Groombridge Estate of Mira Jelin The DiMenna Foundation, Inc. Trust of William Forbes Mr. and Mrs. Martin D. Gross Robert Charles Jenkins Elizabeth R. Miller and James Foundation 14 Trust of William Gross The JMB Hope Foundation G. Dinan and The Dinan The Evan Frankel Foundation Shoshanna Gruss The Robert Wood Johnson Family Foundation Mr. and Mrs. Lewis Frankfort Gurwitch Products Foundation William C. Dowling, Jr. Trust of Jill and Jayne Robert C. Halboth Estate of Robert L. Jones Foundation Franklin Mrs. Melville W. Hall Max Kade Foundation, Inc. Dr. Scholl Foundation Frazier Foundation Trust of Kenneth L. Hallam Eugene S. and Constance Kahn Mr. and Mrs. Adam Dunn The Edna R. Fredel Charitable Trust of Florence M. Hammer The Kahn Charitable Trust of Francis C. Dykeman Lead Annuity Trust Trust of Robert Hanson Foundation Marie E. Dykeman Estate of Frank O. Fredericks Mr. and Mrs. Jose Kuri Harfush Kaleidoscope of Hope Estate of Laura D. Eastman Free to Breathe Harrington Discovery Institute Foundation The Eberstadt-Kuffner Fund The Fribourg Foundation Susanne and Shelley Harrison Estate of William Kanter Inc. Estate of Gerard M. Friedman Mr. and Mrs. Robert L. Edward M. Kaufmann ECD Global Alliance The Anna Fuller Fund Harteveldt Linda and Ilan Kaufthal Mr. and Mrs. Thomas J. Richard M. Furlaud Trust of Abraham Hases Estate of Helen Keena Edelman Estate of Leonard Galasso Estate of Katherine Hawrylow Trust of Fenton O. Keister The Edelman Family Estate of Regina M. Gallichio Estate of Irma Hayes Robert J. Keller Eli Lilly & Co. Estate of Norman D. Galloway Austin D. Hearst J. C. Kellogg Foundation Estate of Rita H. Schaefer Mr. and Mrs. Robert M. Hecht and Company The John R. Kennedy Elliott Gardiner Philanthropic Fund Foundation Empire Blue Cross & Blue Trust of Esther B. Garnsey Mr. and Mrs. Charles Kern Family Fund Shield Trust of Frances L. Gatterdam Heimbold, Jr. Estate of Patricia A. Kerrigan The Charles Engelhard Estate of Mildred B. Gehrke Cherie Henderson and David The Kettering Family Foundation General Atlantic Foundation Poppe Foundation Esophageal Cancer Education The Patrick A. Gerschel Hendrickson Family Estate of Ursula A. Kildea Foundation Foundation Foundation Trust of Estelle Knapp Trust of June K. Evans Leonardo Giambrone Heyman-Merrin Family Trust of Paul and Fran Knight Trust of Lillian Evans The Albert and Pearl Ginsberg Foundation The Kohlberg Foundation Lord Evans of Watford Foundation Brian J. Higgins The Greater New York City Trust of Sarah W. Ewing Liane Ginsberg The Hillcrest Foundation Affiliate of Susan G. Komen Mr. and Mrs. Barton Faber GIST Cancer Awareness James and Angela Ho for the Cure Estate of Giuliana Fantini Foundation The Catie Hoch Foundation The Kors Le Pere Foundation Trust of Mary E. Farrell The Glades Foundation Estate of Laverne Hodges Joel Koschitzky

70. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

The Gwen L. Kosinski Estate of Julian Malkiel Yvonne and Arthur Moretti Precision Medicine Research Foundation John Magnier Ronald and Brenda Morey Associates Mr. and Mrs. Marvin H. Koslow Estate of Albert Manning Trust of Edmund L. Murray Trust of Helen M. Price The Fred W. Kramer Charitable Trust of Jack & Ruth Marcus Edith L. Nathanson Estate of Seymour Price Trust Estate of Marvin Margolies Trust of Louise F. Neely Prudential Financial, Inc. Mr. and Mrs. Robert A. Kramer Mrs. John L. Marion Craig H. Neilsen Foundation Trust of Raymond F. Prussing Mr. Kenneth Kret Susan and Morris Mark Estate of Gwendolyn L. Robert Pufahl Cheryl Gordon Krongard Trust of Sarah H. Marks Nekrewich Purdue Pharma LP Trust of Walter C. Kronke The Marmot Foundation Estate of Ann M. Nelson Patricia A. Quick Charitable Estate of Ann Kuhlmann Estate of Edith Lipphardt Jerome and Elaine Nerenberg Trust Estate of Harriette H. Kussin Martens Foundation Stewart Rahr Estate of Sidney Lacher Estate of Elizabeth Martin Muriel Neumann Trust of Harriet C. Rath The Lakeside Foundation Trust of Richard and Betty Neuroendocrine Tumor Bonnie Reiss and Family Mr. and Mrs. Joseph M. La Martin Research Foundation Trust of Anne Ressner Motta Estate of Ann L. Martinez The New York Stem Cell Estate of Walter E. Rex III Estate of Harriet L. Lampert The Lucille and Paul Maslin Foundation The Rice Family Foundation Trust of Ella B. Larsson Foundation The Newport Foundation Anne S. Richardson Fund Vivian F. Laube Trust of Cecelia Matarazzo Estate of Jane M. Nicholson The Ritter Family Foundation Lavelle Fund for the Blind, Inc. Estate of Michael Matchen Trust of Florence S. Nilsson Irene Ritter Foundation Betty Reid Lawson Mr. and Mrs. Howard A. Matlin James G. Niven Trust of Lillian Robbins The Iris and Junming Le Estate of Harry H. Maus Fred and Gilda Nobel Mr. and Mrs. Stephen Robert Foundation Paul S. May The Lyla Nsouli Foundation Robin Hood Foundation Lead Annuity Trust The Mayday Fund for Children’s Brain Cancer Estate of Sandra Sheppard Trust of Joseph Lebednik The Helen & William Mazer Research Rodgers The Richard S. and Karen Foundation The Oceanic Heritage Estate of Ellen S. Rogoff LeFrak Charitable MBNA America Bank Foundation Kenneth C. Rohan Foundation The MBNA Education Trust of Robert M. Ochs Ginni Rometty In memory of Stacey Leondis Foundation Mr. and Mrs. Wm. Montague Estate of Nathan Rothstein Estate of Donald LeRoy Mary Jane McCarthy Oeste, Jr. Estate of Wilhelmina T. Rouget Leukemia Research The Michael W. McCarthy The Okonite Company Trust of Cecile N. Ruben Foundation Foundation Grace Oughton Cancer Trust of Maurice Ruben Estate of Barbara Grande Mr. and Mrs. Thomas R. Foundation The Selma and Lawrence LeVine McCullough The William & Jane Overman Ruben Foundation Trust of Leona Levy Estate of John C. McDaniels Foundation Andrew Sabin Family Bertha and Isaac Liberman Mr. and Mrs. Jay H. McDowell Eileen and James A. Paduano Foundation Foundation, Inc. Estate of Charles McGreevy Parfums de Coeur Ltd. Mrs. Orhan I. Sadik-Khan The Anne Boyd Lichtenstein Estate of Mary T. McKibbin The PaulieStrong Foundation Mrs. Edmond J. Safra Foundation Estate of Alan McMaster Rosalind and Kenneth Mr. and Mrs. Herbert E. Saks Estate of Helen Lieber Laura Mercier Ovarian Cancer Pearlman Mara and Ricky Sandler Estate of John E. Liebmann Fund Richard S. Pechter Isabella Santos Foundation Mr. and Mrs. Richard The Reuven Merker Charitable PepsiCo Foundation, Inc. Trust of Erika Saphier Lightburn Foundation, Inc. Estate of Ann Perkins Trust of Paul C. Sawyer Young Ae Lim and Joonsikk Estate of Despina Messinesi Estate of Claude E. Petruzzi Trust of Edwin & Grace Sayers Moon Mr. Robert A. Metzler Mr. Donald Pfanz Estate of Christine C. Scanlan Pauline H. Lin Trust of Russell H. Michel Pin Down Bladder Cancer Trusts of Anabel M. Linda Lipay Mr. and Mrs. Richard A. Miller Alicia and Corey Pinkston Scarborough and Walter L. Estate of Marian J. Looser Mrs. Minot K. Milliken Mr. and Mrs. Jeroen Scarborough Lostritto Family Melissa and Robert Mittman Henk L. Pit The Milton Schamach Milton Lowenstein Francois Wallace Monahan Estate of Jean D. Pitcher Foundation, Inc. MacDonald-Peterson Estate of Dorothea K. Money Jerry W. Pittman Mr. and Mrs. Stephen Scherr Foundation Trust of Anny S. Moore Estate of Elizabeth Polotaye Trust of Edward and Irene MacMillan Family Foundation Diana M. Moore Schlosser

71. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Jennie C. Schneider Trust of May Strang Effie Wells-Lonning Alliance for Life Sciences Rob and Karen Schneider The Daniel P. Sullivan Clinical Trust of Ida Wharton & Health Mrs. Silvia A. Schnur Fellowship Fund Estate of Ann White Estate of Lori S. Alper Mr. and Mrs. Paul C. Schorr IV Timothy P. Sullivan Charitable Whitehall Foundation Mr. and Mrs. Robert I. Alpern Estate of Evelyn Schrank Lead Trust John C. Whitehead Sheikha Noura Alsheikh Trust of Crystal Schull Susquehanna Foundation Estate of Ruth Whitfield The Amaturo Foundation, Inc. Estate of Bertha Schulman Trust of Hazel L. Sutton William F. and Barbara K. American Express Foundation The Schultz Foundation The Taft Foundation Whitman American Federation for Aging Mr. and Mrs. John W. Scully The Paula Takacs Foundation The Helen Hay Whitney Research Searle Scholars Program for Sarcoma Research Foundation American Heart Association The Selander Foundation Frank N. Tedesco Mr. and Mrs. Frank C. American Lung Association The Select Equity Group Estate of Ida Tepper Whittelsey III American Urological Foundation Trust of Annette M. Terdina The Jesse R. Wike Charitable Association The Nina and Ivan Selin Family Estate of Stella R. Thater Trust Amgen, Inc. Foundation Think Pink Rocks Kendrick R. Wilson III Estate of Maurice Amzalak Estate of Sam Seltzer Thrasher Research Fund Mr. and Mrs. Jon Winkelried Mr. and Mrs. Harold F. Mr. Frank Senior Mr. and Mrs. Carl W. Timpson, Elizabeth Winterbottom Anderson Seventh District Association, Jr. The Winters Family Fund Richard and Peggy Anderson Inc. Estate of Michael Z. Toman Wooden Nickel Foundation Warren and Lillian Anderson Estate of Gladys N. Severud The Robert Mize & Isa White Trust of Vincent J. Zappolo Anonymous The Shanken Family Trimble Family Foundation The Zickler Family Foundation Mr. and Mrs. Jerome V. Ansel Foundation Mr. Steven Trost Estate of Robert E. Ziegler Anthony Brands Estate of Odette Sharow Trust of Irwin C. Unger Nicholas B. Zoullas The Antonacci Family Trust of Minnie M. Shaw United Hospital Fund Mr. and Mrs. Jeffrey A. Zucker Foundation Hope Sheridan Foundation of New York Estate of Marilyn Apelson Renee and Irwin Shishko United Leukemia Fund Inc. Maite Aquino Memorial Fund Estate of Lillian M. Siemionko United Way of New York City Mr. and Mrs. Rand V. Araskog The Grace, George, and Judith The Lucy & Eleanor S. Upton $100,000 — $249,999 Trust of Theodocia D. Arkus Silverburgh Foundation Charitable Foundation 4Love Project Mr. and Mrs. William J. Trust of Leonard & Ruth Estate of Monique Uzielli A & P Foundation Armfield IV Silverman Nancy and Nicholas Valeriani Mr. and Mrs. Ghazi Abbar Paul Armin Family Foundation Leonard and Donna Simon The Vasey Foundation Abbott Laboratories Nicole Sinek Arnaboldi and Leo SIR Foundation Veejay Foundation The Louis & Anne Abrons Arnaboldi Trust of Angie S. Skinner Estate of Eleanor B. Vogel Foundation, Inc. Kym S. Arnone The Alan B. Slifka Foundation Voices Against Brain Cancer Jean Ackerman The Aronson Family The Gordon H. and Norma Foundation Estate of Michael Ackerman Foundation Smith Family Foundation Douglas Walker Acorn Foundation Mary Kay Ash Charitable Estate of Robert A. Smith Estate of Muriel F. Wall Mr. and Mrs. William R. Foundation Estate of Roberta A. Smith The Bert & Sandra Wasserman Acquavella The Isaac and Carol Auerbach Ms. Beryl Snyder Foundation Mr. and Mrs. Laszlo Adam Family Foundation The Seth Sprague Educational Marla J. Wasserman The Aetna Foundation Autism Speaks and Charitable Foundation Samuel Waxman Cancer The Francis X. Ahearn, Sr. AVIESAN Trust of James L. Stackhouse Research Foundation Foundation The Ayres Baechle Foundation Arthur A. Stamm The Sue Ann and John L. Roger and Elizabeth Ailes Mr. and Mrs. Charles Ayres The Robert Steel Foundation Weinberg Foundation Trust of Eileen I. Alessandrini Trust of Maureen E. Bacchi for Pediatric Cancer Research The Scott Weingard Memorial Daniel G. Alexander Dr. Joseph J. Bailey Trust of Frederick T. Steinberg Fund The Shana Alexander Elliot A. Baines The Jeffrey Steiner Family Mr. and Mrs. Boaz Weinstein Charitable Foundation The Baird Family Fund Foundation Estate of Elias Weiss Mr. and Mrs. John P. Allen Mrs. Judy K. and Mr. Jack The Guy M. Stewart In memory of Marie T. Weiss Robert and Elaine Allen W. Baker Cancer Fund John A. Weissenbach and Ann AllianceBernstein The Solomon R. and Rebecca D. Estate of Sonia Stolin-Moresco Southworth Baker Foundation

72. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

David M. and Barbara Baldwin Trust of Raymond Blake The Brownington Foundation Casual Male Corp. Foundation Inc. Blaker Family Fund Estate of Vernon Brunelle Catch 25 Foundation, Inc. Ariela and Mendel Balk Hector Payares Blanco Elizabeth Bucher Catwalk 4 Cancer Estate of David B. Ballard Bill Blass Licensing Company, The Peter & Carmen Lucia The Cayuga Foundation Estate of Harold P. Bannister Inc. Buck Foundation Estate of Charlotte A. Celian Mr. and Mrs. Robert L. Mr. and Mrs. Jeff T. Blau Estate of Edwin Buckingham Mr. and Mrs. E. Val Cerutti Barbanell Madeline and Alan S. Blinder Melva Bucksbaum and Trust of George F. Chagnot Trust of James R. Barber Ambassador and Mrs. Alan J. the Robert I. Goldman Trust of Henry D. Chaikin Estate of Lucille H. Barbour Blinken Foundation Dr. Kalpana Chakraburtty Barish Family Foundation Mr. and Mrs. James A. Block Janna Bullock Chanel, Inc. Trust of Grace M. Barry Estate of Vivian K. Blonder Mr. and Mrs. Roy R. Margaret Anne Chappell Estate of Kaethe F. Barry Trust of George Bloostein Bumsted III Charina Foundation Estate of Patricia A. Barry Edith C. Blum Foundation, Inc. Trust of Florence Bunn Tribhuwan N. and Sadhna Estate of Robert B. Bartow The Walter & Adi Blum Mr. and Mrs. Franz H. Burda Chaturvedi Mario Batali Foundation Foundation, Inc. Mrs. Coleman P. Burke Michael and Pamela Chepiga Trust of Eileen L. Batten Trust of Eli Blumenfeld Trust of Dorothy A. Burkert Estate of Camille Chericone Trust of Joyce A. Battle Harold and Adele Estate of Louise V. Burnett Chesed 24/7 The Modestus Bauer Blumenkrantz Mr. and Mrs. Harold Busch Child Neurology Foundation Foundation Estate of Simon P. Blustone Mr. and Mrs. Jonathan J. Bush Childhood Brain Tumor Trust of Ruth M. Baughman D. Dixon Boardman Estate of John D. Bush Foundation Lynn B. Bayard Bruce Bocina The Paul Nabil Bustany The Children’s Brain Tumor Be the Difference Foundation Estate of Marti A. Boden Foundation Foundation Estate of Thelma Beatty Peter Bodok Estate of Ruth J. Butterworth Children’s Neuroblastoma Trust of John A. Beaty Estate of Alan A. Bohlinger Estate of Lillian A. Byman Cancer Foundation Mr. and Mrs. Edmund Becker Estate of Marjorie R. Boselly Mr. and Mrs. Bruce L. Calhoun The Francis and Miranda Lisa J. Becker and Anthony The Boston Foundation Mr. and Mrs. Jeremiah M. Childress Foundation M. Pesco Estate of Lydia Botfeld Callaghan The Jane Coffin Childs Estate of Charles R. Beechler Alan F. Bovee Trust of Marilyn Campbell Memorial Fund for Medical Trust of Kathe Begeest Trust of William R. Boyle The Cancer Couch Foundation Research Laurence D. Belfer Estate of Mary C. Brabson Cancer Research & Treatment Chordoma Foundation The Robert & Renee Belfer Estate of Elsie L. Bradford Fund Estate of Selma Chyatt Family Foundation The Bradshaw Family Leah Rush Cann William Joseph Ciliberti Estate of Robert D. Bennett Brahman Capital James A. Cannon Judith Ann Cion Revocable Corinne Berezuk and Michael Brain Tumor Funders’ Estate of Edward A. Cantor Trust Stieber Collaborative Paul T. Cappuccio Estate of Piera Circiello Trust of Isidore Bergner Anna M. and Mark R. Brann Michael and Carol Carey Amanda Styles Cirelli Mr. Bernard S. Berkowitz Mr. and Mrs. Henry R. Breck Carlsberg Foundation Foundation for Pediatric Joan and James Berkowitz Milton Brenner Trust of Jacqueline Carnrick Cancer Research Fund Mr. and Mrs. Fred J. Mr. and Mrs. Edmund M. Mr. and Mrs. Robert Citrone Berkowitz II Foundation Brettschneider Carpenter The Anne L. and George H. Estate of Tony P. Bernabich Estate of Mae Bridewell Mr. and Mrs. Warren E. Clapp Trust The Bill Bernbach Foundation The Broder Family Foundation, Carpenter III Estate of Lyman W. Clardy Steffi and Robert Berne Inc. Estate of Eugene Carrara Mr. and Mrs. Neil A. Clark Mrs. Louis Bernstein Estate of Edna Brodie Estate of Irene A. Carson Estate of Ina Clarke Luciano and Giancarla Berti Tom and Meredith Brokaw Estate of William K. Carson Estate of Mary M. Cleary Jacqueline Bikoff Randall Brooks Mr. and Mrs. William M. Cleveland Clinic Health System Estate of Margaret L. Bingman Brown Helicopter, Inc. Carson CLL Global Research Biomet Carl and Nickey Brown Estate of Colon B. Carter Foundation Trust of C. June Bisplinghoff Trust of Ruth Ann Brown Trust of Winifred T. Carter Trust of David Cohen BJ’s Charitable Foundation Estate of William A. Brown, Sr. Estate of Elsie Cartotto Mr. and Mrs. Laurence Bladder Cancer Advocacy Ms. Betsy Levine-Brown and Joan (Perkowski) Cashin W. Cohen Network Mr. Marc Brown Foundation

73. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Clarence L. Coleman Jr. Mrs. Charles A. Dana, Jr. The Andree Wildenstein Mr. and Mrs. James T. Fantaci and Lillian S. Coleman Estate of Richard Daniels Dormeuil & Roger Dormeuil Joyce Fefferman Foundation The Gloria and Sidney Danziger Foundation Estate of Marion E. James J. Coleman, Jr. Foundation, Inc. John R. Doss Feigenbaum Estate of Gertrude T. Coles Estate of Hannah Danziger Percy S. Douglas The Alfred & Harriet Feinman Karen Collias and Geoffrey The E. S. P. Das Foundation Estate of Susie M. Downing Foundation Levitt Barbara A. Dauphin Mr. and Mrs. Frank P. Doyle Gretchen V. and Samuel M. Robert and Maryann Collin The Davee Foundation Trust of Max Drechsler Feldman Estate of Arthur R. Collins Estate of Paul D’Aversa Dreyer’s Grand Ice Cream, Inc. The Corinne Feller Memorial Estate of Lila V. Collins Estate of Hazel Davidson Estate of Donald E. Drinkwine Fund The Colon Cancer Foundation Mr. and Mrs. Scott E. Davidson Jane Clausen Drorbaugh Trust of Robert I. Fendrich James J. Colt Foundation, Inc. The Ellen and Gary Davis Dr. Jeffrey Duban Roger W. Ferguson, Jr. Comerica Charitable Trust Foundation Trust of Anne Duerden Trust of Thelma F. Fernandez Community Foundation for Trust of Jane Davies Trust of Patricia P. Duffy Fetzer Institute Greater Atlanta Trust of Hermine S. Dawson Estate of Doris M. Dunham Trust of Lydia K. Fiedler Condé Nast Publications Roxana V. Dawson Margaret H. Dunwiddie Randee and Howard Fischer Estate of John Confort, Jr. Estate of Sara De Castro The Durst Organization, Inc. Estate of James K. Fisher Mr. and Mrs. Alexius Conroy Estate of Karin D. de Chellis Estate of Evelyn J. Dyba Estate of Nellie G. Fishman Consolidated Edison Company Estate of Jean Decker Thomas Edelman Estate of William and of New York Estate of Libiro DeFilippis Doris M. Edwards Frederica Fissell Dudley P. Cook The Lawrence and Florence E. E. Cruz Company Trust of Loretta B. Fitzgerald Mr. and Mrs. Errol M. Cook DeGeorge Charitable Trust Mr. and Mrs. Blair W. Effron Mr. and Mrs. Thomas M. Trust of Kristen H. Cook The DeGregorio Family Trust of Bertram Ehrlich Fitzgerald III Mrs. William B. Cook Foundation Trust of Raymond Ehrlich James B. Flaws and Marcia D. Mr. and Mrs. E. Gerald Cooper Lynn DeGregorio Estate of Elinor Ehrman Weber Estate of Morris Coppersmith Mr. and Mrs. Roberto de Estate of Greta Einhorn The Francis Florio Fund of the Estate of G. R. Couch Guardiola Albert Eisenberg Foundation New York Community Trust Mr. and Mrs. Paul Coulson Estate of Katherine C. DeHaan Trust The Mary Alice Fortin Courtesy Associates, Inc. Goff Estate of Estelle Eisenstat Foundation The Cowboy Fund Anthony Del Bove Mr. and Mrs. Frederick Richard N. Foster Anne Cox Chambers The Delaney Family Elghanayan Trust of Aida A. Foti Foundation Estate of Helen Demitriades Martin Elk League for Cancer Foundation for Women’s Estate of Edith C. Cox Mr. and Mrs. Steven Denning Research Cancer Trust of Burton L. Craig, Jr. The Derfner Foundation Trust of Arnold B. and Joan S. Four Seasons Hotel – New York Trust of Franklin C. Craig Ernst and Paula Deutsch Elkind The Fan Fox and Leslie R. W. Michael and Lois Craig Foundation Mr. and Mrs. Richard S. Emmet Samuels Foundation, Inc. Credit Suisse Group Thomas and Margaret DeVita Andrew J. Entwistle Amy K. Foy and Nicholas J. Trust of Louise Crites The DeWitt Wallace Fund EOS Products, LLC DeFlora Crohn’s & Colitis Foundation of Mr. and Mrs. Anthony Diaco Estate of Lillian Epps Estate of Thomas R. Foy America The Miriam & Arthur Diamond Mr. and Mrs. Christopher Maria Frangella Foundation The Crown Family Charitable Trust Errico for Colon Cancer Research Bruce Crystal The Ernest & Jeanette Dicker Rafael Etzion Claire and Meyer W. Frank and Trust of Leroy & Barbara Foundation The Charles Evans Foundation Leann Frank Cubicciotti Estate of Margaret DiDonato Estate of Eugene M. Evans, Jr. Charitable Foundation Cure Alzheimer’s Fund Estate of Richard I. Diennor The Evslin Family Foundation Trust of Irene R. Frank Mr. and Mrs. James F. Trust of Mary L. Dillon Expect Miracles Foundation Nicole and Steve Frankel Curtis III Discavage Family Foundation Trust of James D. Ezzell Helen Frankenthaler Cusa Realty, LLC Mr. and Mrs. Daniel Gloria B. Falkson Foundation Custom Design L. Doctoroff Family Reach Foundation Mr. and Mrs. David Lee Communications, Inc. Oliver S. & Jennie R. Donaldson Fanconi Anemia Frankfurt William J. Cwenn Charitable Trust Research Fund Trust of James and Mary Mark and Elizabeth Czarnecki Estate of Maurice A. Donovan Mr. and Mrs. Alfonso Fanjul, Jr. Frankhouser

74. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Mr. Edward W. Frantel Ms. Miriam Goldman Estate of Gloria E. Gurney Estate of Robert Hensel, Jr. Doreen Frasca and Tom Mead The Barbara L. Goldsmith Gurney Foundation Estate of Antje Hensen Estate of Gloria Freed Foundation Mimi and Peter Haas Fund The John & Rose Herman The Freed Foundation Shelley and Graham Goldsmith Helen and Samuel Haber Foundation Estate of Katherine Freeman Lawrence Goldstone, MD Hachette Filipacchi Media U.S. Carolina Herrera, Ltd. Mr. and Mrs. Sanford Freiman Trust of Manuel and Anne Jayma Meyer Hack and Bruce Trust of Leon Hershaft Frey Family Foundation, Inc. Goodman L. Hack Estate of Rita Hertzig Zoltan Fried Google The Hagedorn Fund Ms. Marlene Hess and Mr. Jim Susan and Fred Friedman Trust of Steve Gorczyca The Laverna Hahn Trust Zirin Estate of Eugenie Fromer Christy and Sheldon Gordon Estate of Margaret S. Hahn Trust of Marie Hesselbach Charles A. Frueauff Foundation The Gordon Family Hairy Cell Leukemia Heymann-Wolf Foundation Estate of Bella Frutkin Foundation, Inc. Foundation Trust of Gerald R. Hiering Estate of Roger M. Furiness Trust of Louise S. Gosse Martin and Deborah Hale Estate of Manny Hilfman Estate of Joseph F. Fursa, Jr. Marietta A. Goulandris Estate of Elizabeth W. Hall Hillenbrand Family Mr. and Mrs. Thomas J. Gahan Eileen F. Gould and Robert J. Estate of Mazie J. Hall Foundation Trust of Ralph W. Gaines Dwyer Estate of Helen Sue Mrs. John S. Hilson Estate of Anne Gallagher Julie Gould Fund for Medical Hameetman The Mark Hindy Charitable Anita C. Garoppolo Research Jeanne G. Hamilton and Foundation Mr. and Mrs. Julius R. Gaudio Estate of Richard P. Gould Lawson W. Hamilton, Jr. Trust of Myfanwy Hinkle GC for a Cure 5K Run/Walk Grantham Mayo Van Otterloo Family Foundation, Inc. The Hippodrome Dry Cleaning Bruce G. Geary Foundation & Co. Milton and Miriam Handler Histiocytosis Association Trust of Louis C. Geiger Estate of Harvey R. Graveline Foundation Estate of Vladimir Hladik Trust of William G. Genner, Sr. Stephen and Myrna Greenberg Estate of Stanley E. Handman Estate of Edward B. Hodge Kara and Peter Georgiopoulos Brigadier General and Mrs. Trust of Elaine A. Hansen Estate of Agnes S. V. Hoffman Estate of Jacques A. Gerard William S. Greenberg Estate of Marion K. Hardwicke Estate of Marion Hoffman Robert and Sylvia Gergen The Greenberg Breast Cancer Estate of Mary Jane Estate of Ruth M. Hoffman Estate of Charles J. Gerhart Research Foundation Harrington Trust of Steward B. Hoffman, Panayotis Gerolymatos Estate of Helen S. Greenwood The Mary W. Harriman Sr. Trust of Alda Getti Mr. and Mrs. Peter S. Gregory Foundation Hoffman-La Roche Inc. Estate of Theresa A. Trust of Dorothy G. Griffin Leonard B. Hart Deborah H. and Sigmar K. Ghiringhello John and Amy Griffin Laura Hartenbaum Breast Hofmann Judith Gibbons and Francesco Foundation Cancer Foundation Hope V. Hofmann Scattone Mr. and Mrs. Melvin W. Griffin Mr. and Mrs. William R. Richard Hogan and Carron The Ryan Gibson Foundation Trust of William C. Griffith, Jr. Hartong Sherry Marlene and Alan Gilbert Trust of Vernon H. Grigg The Abbe & Lloyd Hascoe Mrs. Carolyn T. Holden Gilead Sciences Grodetsky Family Foundation Foundation Trust of Burt Holtzman Estate of Rosemarie M. Gilman Estate of Evelyn Gross Have A Chance, Inc. Howard and Carol Holtzmann Mrs. Bruce A. Gimbel Estate of J. Stanley Gross Trust of Peter J. Hayes Estate of Margaret Hooghuis Trust of Adele Ginsburg Trust of Lambert J. Gross Haymakers for Hope Estate of Herman L. Hoops Mr. and Mrs. William H. Girvan Estate of Anthony Grosso Morris A. Hazan Family Trust of Anita S. Horbacz The Harvey S. Gitlin Family Trust of Bernice I. Grossteiner Foundation Alfred Samson Hou Foundation Allen J. Grubman HCCF Foundation Robert Howard Family Gail C. Gittleson Audrey and Martin Gruss Mr. and Mrs. Andrew P. Heaney Foundation Estate of Grace E. Glenn Foundation Trust of Lonie G. Hearn Estate of Frank Huber Glenwood Management Estate of Wanda Grzymala The Per and Astrid Heidenreich Nancy Hughes Corporation Guardsmark, LLC Family Foundation Humanscale Corporation Trust of Carmen Gobbi Marilyn B. Gula Mountains of Trust of Shirley S. Heiligman Estate of Edna Hunt Trust of Glenn R. Gobble Hope Foundation Mr. and Mrs. Robert M. Carol Hunter Christina and Peter Gold Estate of Pauline R. Gulau Hendrickson Constance D. Hunter The Goldhirsh Foundation Trust of Elizabeth Guon Mr. and Mrs. John Hennessy Estate of Edith M. Hunter Goldhirsh-Yellin Foundation Drs. Satyendra and Manjula The Maxine R. and Richard L. James B. Hunter Estate of Elizabeth B. Golding Gupta Henry Trust I Back Jack Foundation, Inc.

75. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

IBM Employee Services Center The Lawrence Kaplan and Mrs. Mitzi Koo Laurence W. Levine Zapfel Fund Marilyn Kaplan Foundation Nancy Koodish Foundation Mr. and Mrs. David W. Ichel Marie H. Karger The Koppelman Family Estate of Dina Levinsky Estate of Priscilla T. Iden The Karma Foundation Foundation Elvire Levy Inamed Corporation George Karnoutsos Robert A. Kotick Estate of Erna T. Lewine Incyte Corporation Trust of Jerry Katz Kovler Family Foundation Mr. and Mrs. Robert Liberman Ingersoll Rand Company Trust of Toby Katz Mr. and Mrs. Bruce S. Kovner The Marvin and Kay Lichtman Mr. and Mrs. William H. The Katzin Foundation Oliver Kramer Foundation Ingram Trust of John Kaufmann, Jr. Trust of Clara R. Kraut Light of Life Foundation International Myeloma Trust of Ralph W. Kaufmann Enid and Richard Kreindler Trust of Wilhelmina I. Lipfert Foundation Mr. and Mrs. Robert M. Kavner Mr. and Mrs. Jerome I. Kroll Mr. and Mrs. Ira A. Lipman Irish Society of Medical Carl Michael Kawaja and Trust of Grace E. Kruse Lisa’s Heart Kids’ Cancer Oncology Gwendolyn N. Holcombe Mr. and Mrs. David Kuhns Research Fund It Figures LLC Thomas F. Kearns Lee and Murray Kushner The Harold I. & Faye B. Liss Jacobus-Iacobucci Foundation Charles L. Keith & Clara Miller KVFF Fund Foundation Estate of Harold F. Jaeger Foundation Mrs. Thomas G. Labrecque Mr. and Mrs. Martin Liss Mr. and Mrs. Stanley R. Jaffe Trust of Jacquelin J. Kelly Estate of Sidney J. Lacher The Lucius N. Littauer Thomas Jaffe Estate of Ruth C. Kelly Estate of Schubert L. Lamb Foundation James Family Foundation Mrs. Ann Kelman and the late Deborah and Peter Lamm The Litterman Family JDRF Dr. Charles D. Kelman Estate of Marvadene B. Foundation Trust of Ann E. Jennings Kemmerer Family Foundation LaMonica Estate of Seymour Litwack Richard H. Jenrette Eleanora and Michael Kennedy The Edward & Kinga Lampert Shaojun Liu The Jewish Communal Fund Peter Kenner Family Fund Foundation Live, Love, Laugh Foundation Jewish Federation of Cleveland J. Kevin Kenny Mr. and Mrs. Barry Lang Estate of Santina Livolsi JMCMRJ Sorrell Foundation Kensico Capital Management Estate of Annie Langen Demarest Lloyd, Jr. Foundation Mr. and Mrs. Peter James John A. Kent Estate of Anne Lanigen Lloyds Banking Group Johnson, Jr. Estate of Herman Kerner J. Clair and Pamela Lanning Jeanette and Peter Loeb The Samuel C. Johnson Trust Estate of Charles L. Kerstein Mr. and Mrs. Mark Laracy Stephanie and James Loeffler Mr. and Mrs. Roy J. Johnston The Glenn D. Kesselhaut The Matthew Larson Long Island League to Abolish Robyn and Ken Joseph Children’s Joy Fund Foundation for Pediatric Cancer J.P. Wish Fund Estate of Mary F. Kessler Brain Tumors Estate of Margaret S. Longwell Judges and Lawyers Breast Mr. and Mrs. Peter A. Kessler Dr. Gerald D. Laubach Estate of Elizabeth Loos Cancer Alert Coyla E. Ketchy Mrs. Lois H. Lazaro Estate of Anthony Lopez Juvenile Diabetes Research Estate of Henri Khouri The M.J. & Caral G. Lebworth Mr. and Mrs. José Luis Los Foundation International Mr. and Mrs. Charles Khoury Foundation Arcos Trust of Frank J. Kahn Doris and Floyd Kimble Trust of Edwin S. Lee, Jr. Dr. Christine B. Loveland Trust of Nina M. Kaiser Foundation Mr. and Mrs. Thomas V. Leeds James J. and Marianne B. Jane Kalmus The King Family Charitable Gary Leet Lowrey Harry P. Kamen Family Lead Trust The Lefkofsky Family The Lucerne Foundation Foundation Mr. James W. Kinnear II Foundation Cynthia and Dan Lufkin Mr. and Mrs. Daniel B. Patricia A. Kirby Lehman Brothers Inc. Eric and Susan Luse Kamensky Mr. and Mrs. James M. Karen and James Lehrburger Ronald S. Lux Trust of Mildred Kaminsky Klausmann Mr. and Mrs. Lewis E. Lehrman Mr. and Mrs. Alexander P. Estate of Julie Kammerer David L. Klein, Jr. Foundation Ernest E. & Marian E. Lehto Lynch Kanarek Family Foundation Kleinfeld Bridal Corp. Joint Trust Trust of John F. Lynch Estate of Lee L. Kanarian Robert D. Klemme Trust of Martha B. Leigh Estate of Kathleen E. Lynch Estate of Eleanor Kane The Esther and Joseph Estate of Helen Lesniewski Estate of Charles S. Lyons Mr. and Mrs. William Kane Klingenstein Fund The Leukemia & Lymphoma Estate of Melvin E. Lyons Estate of Bernard Kantor Mr. and Mrs. Steven B. Klinsky Society Josiah Macy, Jr. Foundation Steve and Meghan Kanzer Fernand Koch Charles and Margaret Levin Arthur & Holly Magill Estate of Irvin L. Kaplan Estate of Gale K. Kokubu Family Foundation, Inc. Foundation Estate of Elizabeth Koller The Maguy Foundation

76. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

The Arthur I. and Susan Maier Estate of Donald J. McCarraher Carolyn Rosen Miller Family Jane R. Nessen Foundation Estate of Joe B. McCawley Foundation New York City District Council Estate of Margaret E. Maihl Mr. and Mrs. Jeffrey A. Mr. and Mrs. Donald K. Miller of Carpenters Relief and Estate of Margaret H. Mairs McDermott Mr. and Mrs. Larry J. Miller Charity Fund Trust of Helen E. Major Lee McDonald Mr. and Mrs. Matthew Miller New York State Bowling Estate of Mariette P. C. Major McDonald Financial Group Mrs. Mary E. S. Milligan Association Estate of Morris Major Ralph McDonough Monroe & Judith Milstein New York State Fraternal Order Estate of Walter Malen The Dextra Baldwin Philanthropic Fund of Police Foundation Herbert J. Maletz McGonagle Foundation Estate of Dorothy B. Minard New York State Health Estate of Irving and Harriet McGraw-Hill Companies Allen Minsky Foundation Malitson McKeen Fund Leslie M. Modell Gerald L. Nichols and Peter L. Malkin Mr. and Mrs. Edward B. Trust of Nettie Moffenson Jacqueline W. Nichols Elissa Caterfino Mandel McKeough Estate of Catherine Mohan Foundation Karen G. Mandelbaum The McKnight Endowment Estate of Irene Mokrzycki Joseph P. Noonan Estate of Harry Marder Fund for Neuroscience Trust of Celestine Elizabeth Trust of Robert F. Novak Estate of Ida Mae Margolis Estate of Geoffrey McLoughlin Moloney The Nussbaum/Kuhn Trust of Carlton G. Marie Peter F. McManus Charitable Estate of William Monaghan Foundation Edward J. Marino Trust Pauline M. Monteleone The Michael A. O’Bannon Jerome S. and Maria Estate of Mary E. McMaster Arthur R. Montgomery Foundation Markowitz Mr. and Mrs. David B. John and Hee-Jung Moon Estate of James O’Brien Zvi and Linda Markowitz McQueary Estate of Pauline Moor Estate of Ernestine A. Estate of Benjamin Marmer The Meckler Foundation Mr. and Mrs. Charles V. Moore O’Connell Karen Marshon Mr. and Mrs. Keith A. Meister The Gordon and Betty Moore Trust of Dorothy B. O’Connor The Christina & Paul Martin Melanoma Research Foundation Mr. and Mrs. Jeremiah Foundation Foundation Estate of Percy W. Moore O’Connor Estate of Emilie Martin The Melville Foundation Tom & Judy Moore Foundation The Drew O’Donoghue Fund Trust of Richard W. Martin Mr. and Mrs. Prakash Melwani The Garrett and Mary Moran Trust of Emily C. O’Grady Mr. and Mrs. Roman Martinez Estate of Dorris M. Trust Dara and Tim O’Hara IV Mendelsohn Estate of Barbara B. Morgan Estate of Grace O’Hare Dorothy Marx Estate of Irving M. Mendelson Melissa and Chappy Morris Wendy O’Neill Jo-Ann Marx, MD Richard and Ronay Menschel Alfred L. and Annette S. Morse Oki Data Americas, Inc. Estate of Johanna Marx Estate of Lorraine Mensing Foundation Harold N. Openshaw, Jr. Estate of Rita B. Masse Julia and Gilbert Merrill Ken and Linda Mortenson Mr. and Mrs. John D. Opie Mary Jane Massie, MD and Mr. Foundation Estate of Lisa F. Morton The Katie Oppo Research William E. Pelton Estate of Amy Joan Meskin The Owen Moscone Foundation Foundation James Mathos Trust of Ruth W. Metcalfe Mr. and Mrs. George K. Moss Optiscan The Hale Matthews Foundation Mr. and Mrs. Frank A. Metz, Jr. Moss Foundation Estate of Elaine Orbach Trust of Walter J. Matthews Estate of Abby E. Meyer Manuel and Mercedes Mosteiro The Orchard Farm Foundation The Matt’s Promise Foundation Estate of Ursula Meyer Lisa and Marcelo Mottesi Julie and Doug Ostrover Reuben and Rose Mattus and The Emanuel N. Micallef Virginia M. Mueller Otis Elevator Company Doris and Kevin Hurley Foundation Estate of Irving Mulde Mr. and Mrs. Gunnar S. Family Foundation Mrs. Sidney Michael Mrs. Sandy Mulligan Overstrom III Sir Deryck and Lady Va Trust of William M. Estate of Earl Muroff William and Ella Owens Maughan Michaelson Mr. and Mrs. Thomas W. Medical Research Foundation Maverick Capital Charities Trust of Florence B. Mickels Murphy II Mr. and Mrs. Neil Padron Max Mara USA, Inc. Cristine Meredith Miele Ernest Muth Mr. and Mrs. Gregory K. Palm Mr. and Mrs. Hamish Maxwell Foundation The National Genetics Pam’s Pals Inc. Maynard Childhood Cancer The Mike and Steve Foundation Foundation, Inc. Daniel P. and Nancy C. Paduano Foundation Elaine P. Miles NBC Universal Family Foundation Mr. Michael Mazzucca Eleanor F. Miley Trust of Joshua Needelman Mr. and Mrs. Jordan M. Pantzer Estate of Ralph L. McBean Romeo Milio Lynch Syndrome Estate of Leslie A. Nelkin The Parnassus Foundation Estate of Ann C. McBride Foundation Trust of Jerome Nerenberg Rosalie Pataro

77. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Trust of Edith Pattison Richard I. Purnell Fund The Fannie E. Rippel Estate of V. Edward Salamon Estate of Herman L. Paul, Jr. Bambi Lyman Putnam Foundation Mr. and Mrs. Eugene L. Salem Pediatric Brain Tumor Trust of Anna Marie Putti Estate of Norma Risman Mr. and Mrs. William R. Foundation The Quain Family Abigail Rittmeyer Salomon Pells-Mayton Foundation Roselyn Flaum Radcliffe The RMF Family Fund, Inc. Trust of Rose K. Salzwas Trust of James A. Pemberton Trust of Samuel J. Radcliffe, Jr. Bernard and Elaine Roberts Samourkas Foundation of New Mrs. Richard T. Perkin Trust of Betty Raiff Estate of Floyd B. Roberts York Mort Perlroth Richard E. Rainwater Trust of Irene M. Roberts Trust of Sidney Samuels Lisa and Richard Perry Norman R. and Ruth Rales Vivien Rock Estate of Henry Sanborn The Pershing Square Foundation Robert and Ardath Rodale Estate of Andrew D. Sanders Foundation Rally Foundation Family Foundation The Sandler Family Sandy and Norman Pessin Mary L. Ralph Philanthropic Rodale, Inc. Nina and Julian Sandler Estate of Ruth Peterson Fund Estate of Maria Rolfe Charitable Fund Estate of Frederick D. Petrie Mr. and Mrs. Edward A. Rankin Sheldon Rose Lt. Colonel (Ret.) Joseph Santa The Pew Charitable Trusts Theodore A. Rapp Foundation Estate of Judith Rosenbaum Barbara Samantha and Ernst Theodore S. Rappaport, P.E., Estate of Sylvia Rosenberg Mrs. Barbara Santangelo Pfenninger Ph.D., NYU Wireless, NYU Trust of Ilsa Rosenblum The Sass Foundation for Trust of Peter H. Pflugk Langone Medical Center Trust of Evelyn Rosenstein Medical Research Mr. and Mrs. Francois de Saint John H. Rassweiler Jeffrey Rosenzweig Foundation The Saw Island Foundation Phalle Abigail T. Reardon for Pancreatic Cancer Estate of Ida M. Scagliarini Phelps Family Foundation Estate of Phyllis E. Redmerski Research Scalamandré Silks Phoebe’s Phriends, Inc. Elenore Reed Leo Rosner Foundation Didi and Oscar S. Schafer Estate of Edmund Piasecki Estate of John Bradbury Reed Estate of Barbara Ross Peter L. Schaffer Trust of Charles V. Pickup Estate of Martha Cuneo Reed Mrs. Howard L. Ross Mr. and Mrs. Charles W. Scharf Estate of Irene Pickup Estate of Samuel P. Reed Estate of Sylvia Ross Estate of Richard Scharff Mr. Alessandro Pinto Compton Rees, Jr. Estate of Eva L. Rothberg Estate of Lee D. Schanbam Mr. and Mrs. Roy R. Plum Odette Regine Foundation Philip and Marcia Rothblum Estate of Sylvia Schatzman Estate of Beatrice Pockrass Christine and Mark Foundation The LeRoy Schecter Estate of John E. Polek Reichenbaum Mr. and Mrs. Eric A. Rothfeld Foundation Mr. and Mrs. Gerard Pompilio Renaissance Charitable Estate of Eleanor S. Rothstein Bill Scherman and Holly Joyner The Ponagansett Foundation, Foundation Estate of Geraldine E. Rove Pasco L. Schiavo Inc. The Beatrice Renfield Denise Rover The Sarah I. Schieffelin Janis Z. Porch Foundation Kylie Rowand Foundation Residuary Trust Cynthia and Gary Porter Mr. and Mrs. Ira L. Rennert Fran and Jeff Rowbottom Estate of Josephine L. Schiff Trust of Ann C. Porterfield Trust of Ruben & Helga Resnik Mr. and Mrs. Charles Royce Mr. and Mrs. David L. Dennis B. Poster Trust of Barbara C. Rex Estate of Pearl Rubin Schlossberg Estate of Edna G. Potter Olivier and Yosun Reza Rose G. Rubenstein Estate of Billie Schneider Estate of John A. Powers The Audrey Rheinstrom and Mr. and Mrs. Mitchell E. Rudin The Schneider-Kaufmann John and Jane Powers Anne Blevins Fund Jane and Mal Rudner Foundation, Inc. Foundation Estate of Roland S. Rhode Estate of Maria Stella Trust of Edward K. Schnepf Trust of Ruth S. Prall Judy Rhulen and Family Ruggirello Adolph & Ruth Schnurmacher Prevent Cancer Foundation Martin Rich Estate of Katherine L. Foundation Rita Price Trust of A. Leslie Richardson Rummler Trust of Lola Schug The Procter & Gamble Dr. and Mrs. Peter C. The Russell Family Estate of Harold B. Schwartz Company Richardson Estate of Roberta Russo Theodore G. Schwartz Family Estate of Ardys M. and Harold Dee Dee Ricks Estate of Eileen B. Ruthrauff Foundation I. Proctor Trust of Margaret L. Rigby The Derald H. Ruttenberg Estate of Rosalind Project Ladybug, Inc. Estate of Evelyn J. Rimosukas Foundation Schwartzbach The William H. Prusoff Estate of Harry Rinehimer Trust of Anne I. Ryan Trust of Paul J. Schwarz Foundation Estate of Elizabeth M. Ringo Martin Sabowitz and Muriel Mrs. Arline Schwarzman Dr. and Mrs. Mark Ptashne Trust of Victoria Rinius Goldrich Mr. and Mrs. Stephen A. Estate of Richard I. Purnell The Saibel Foundation Schwarzman

78. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

Mr. and Mrs. Jeffrey E. Simpson Thacher & Bartlett Mr. and Mrs. Robert A. Staub Team Luke vs. Neuroblastoma Schwendeman Trust Esta Eiger Stecher The Sidney and Loretta Teich Trust of Robert E. Schwenk Trust of Marie A. Sinclair Mr. and Mrs. Edward C. Steele Foundation Trust of Fred J. Scollay Trust of Otto K. & Harriet J. Estate of Sanford L. Steelman Telethon Italy – US Foundation Estate of Jewel C. Seab Singer Estate of Dennis Stein Estate of Walter G. Terwedow Secunda Family Foundation Estate of Shirley Singer The Fred & Sharon Stein The T. F. Trust The Jean & Charles Segal Estate of Madeline Sisia Foundation Thank Heaven Foundation Foundation Estate of Evelyn M. Skolnick Mrs. Nancy Steinfeld Estate of Theresa M. Janet Prindle Seidler Sky Zone Franchise Group The Ernest E. Stempel Thingelstad Foundation SL 2005 Family Trust Foundation Mr. and Mrs. Andrew S. Mr. David Sekiguchi Estate of Alvin F. Sloan The Aaron and Betty Lee Stern Thomas Rena Selden Dr. and Mrs. Bernard E. Small Foundation Estate of Robert P. Thome The Maryam and Hervey Seley Suse Smetana Estate of Irene Stern Trust of Robert W. and Pauline Foundation Louis and Dora Smith Estate of Winona H. Stevens Z. Thompson Rosemary Selky Foundation, Inc. J. McLain Stewart Trust of Vernon Thompson R. B. Sellars Foundation Estate of Mary M. Smith Estate of Rebecca Stohl The Vernon F. & Mae E. Dominique Senequier Mr. and Mrs. Michael S. Smith Mr. and Mrs. Stuart P. Stoller Thompson Charitable Sephardic Hospital Fund – The Randall and Kathryn Mr. and Mrs. Norman L. Stone Foundation Medstar Smith Foundation Stony Wold-Herbert Thrill Hill Productions The Jacqueline Seroussi Mr. Robert J. Smith Foundation Trust of Bridget Tiedman Memorial Foundation Estate of Woodrow Q. Smith Estate of Martha W. Stouffer Tiffany & Co. L. J. Sevin Estate of Dorothy Smolen Estate of Clair B. Stough Mr. and Mrs. Alexander Tisch Harold Shames Catherine M. Smolich Estate of Gene K. Strange The Laurie M. Tisch Estate of Reuben Shane Trust of Robert J. Smutny Estate of Alice K. Straschil Illumination Fund Estate of Elizabeth L. Shanley Mr. and Mrs. Jay T. Snyder Martha Washington Straus Estate of Margaret R. Tomas Trust of Robert A. Shanley Valerie L. Sodano and Harry H. Straus Trust of Bertha Tomaska Regina and Sam Shapiro The Harry & Estelle Soicher Foundation, Inc. Estate of Milton Topolsky Estate of Saul Shapiro Foundation Estate of Herta Strauss Estate of John J. Tormey The Sharma Foundation Trust of Robert Solnick Lauri Strauss Leukemia The Tortuga Foundation Trust of Margaret S. Sharp Solving Kids’ Cancer Foundation Estate of Virginia M. Toth Mrs. Patricia C. Shaw Therese and Marshall Geraldine Stutz Trust Inc. Trust of Angelina Ann Tovar Estate of Bernice Baruch Shawl Sonenshine Trust of Mary R. Suchanski Toys ‘R’ Us Children’s Fund Estate of Alice Sherwin Professor and Mrs. C. Alan Mr. and Mrs. Robert J. Sullivan Mr. and Mrs. David C. Tracey The Shevell Family Soons Trust of George O. Summers Jill Tracey Estate of Leo A. Shifrin, MD Estate of Sharon Sorok Susquehanna Foundation Estate of Rita L. Tracey Mr. and Mrs. Stanley B. Soros Fund Charitable David W. Sussman Trust of Helen A. Trahin Shopkorn Foundation Phyllis and Bernard Sussman Trust of Dorothy B. Traufield Mr. and Mrs. William Shulevitz Sotheby’s Estate of Sandra Syms Beatrice Travis-Cole Mr. and Mrs. Steven J. The Honorable Joyce L. The Sy Syms Foundation The Bud Traynor Memorial Sidewater Sparrow Dorothy D. Taggart Trust Fund, Inc. Muriel F. Siebert Foundation Estate of Manette H. Speas Trust of Andrew Taras The W. James & Jane K. Michael and Susan Siegel Adam R. Spector Foundation Trust of Joyce A. Taras Truettner Foundation Estate of Ruth Siegmann Mr. and Mrs. Richard A. Spelke Edward Tarby Estate of Ina Tuckman Estate of Mary Siekert Trust of Henry Spenadel Target MarkeTeam, Inc. Estate of R. Read Tull Trust of Walter Silberfarb Estate of Regina W. Spence Estate of Ruth N. Taub Lucien L. and Shirley Turk Mr. and Mrs. Robert H. Silver Alvira R. Spencer Taryn Rose International John J. Twomey The Slomo & Cindy Silvian Estate of DeAnne Spencer Tay-bandz, Inc. Ahavas Tzedek Foundation Foundation Estate of Agnes Spillmer Estate of Florence G. Taylor David V. Uihlein, Sr. The Seymour Simon Charitable The St. Giles Foundation Estate of Gertrude S. Taylor Elaine L. Ullrich Trust Trust of Ruth M. Stafford Trust of James M. Taylor Mr. and Mrs. Mark D. Unger Marilyn M. Simpson Charitable Walter Stamm Team Connor Cancer The Unger Family Foundation, Trust Staten Island Yacht Sales, Inc. Foundation Inc.

79. INNOVATION

DONORS TO THE CAMPAIGN FOR MEMORIAL SLOAN KETTERING

The Valley Foundation Marc S. Weinberger Estate of Arthur P. Young Valley of the Sun United Way Stephen L. Weiner Estate of Ellen Youngelson The van Ameringen Danny M. Weinheim Alfred D. Youngwood Foundation The Isak & Rose Weinman Zegar Family Foundation Estate of June A. Vanderpool Foundation, Inc. The Patricia J. and Edward W. Jonathan and Sarah Vanica (GS Estate of Louis Weinstock Zeh Charitable Foundation Gives) Mr. and Mrs. Michael Weisberg The Isaac Ziegler Charitable Varhegyi Foundation Charles and Elyse Weisenfeld Trust The Varnum DeRose Trust Andrew and Ronnie Weiss Stanley Shalom Zielony Dr. Terry G. Vavra and Linda Estate of Gertrude Weiss Foundation F. Vavra Jill and Jeffrey Weiss Martha E. Zimmer In memory of Madeline C. Trust of Gertrude Wellisch Larry and Anne Zimmerman Verducci The Nina W. Werblow Estate of Andrea M. Vernick Charitable Trust Victor’s Three D Estate of Robert L. Werner The Victoria’s Smile Virginia A. Werner Foundation Estate of E. Olga Wesner Trust of Eva Vida Mrs. Elizabeth G. Weymouth Maria von Bothmer Villalba When Everyone Survives The Family of Maria Elena John C. Whitaker Villanueva Estate of Frank A. Widenski Estate of Dorothy Voelker Nancy P. Widmer Trust of Anna L. Vogel Mr. and Mrs. Gene Wilder Estate of Gertrude Vogel Mr. Daniel Wilderman and Ms. Ralph W. Voit Barbara Rockenbach Mr. and Mrs. John Vollaro Wilderness Point Foundation Trust of Beverly Wachtel The Wilf Family Foundation Wachtell, Lipton, Rosen & Katz Andrea J. Will Memorial The Paul E. and Mary Wagner Foundation Trust Trust of Kyle Will Estate of Lillie M. Waldon Barbara F. Williams Wallace Special Projects Fund Mr. and Mrs. Eugene F. Mr. and Mrs. Scott S. Wallach Williams III Mr. and Mrs. Paul D. Walsh Estate of Phyllis E. Williams James M. and Marianne Walter Williams Trading LLC Estate of Frances M. Wanek Trust of Helen A. Wilson Mr. and Mrs. Desmond Wang Helen and Stanley Wissak Estate of Shirley I. Warner Michel C. Witmer Warren/Soden/Hopkins Estate of James B. Wittrock Family Foundation The Henry Wolf Foundation Mr. and Mrs. Bruce Trust of Toby Wolfberg Wasserstein Alice Aeschliman Wolfe Elizabeth T. Wassmundt Mrs. Barbara Wolfson Estate of Shirley F. Watkins Estate of Gordon Wootton Mr. and Mrs. Peter Webster Worldwide Cancer Research Mr. and Mrs. Bradford G. Deborah C. Wright Weekes III Trust of Twylia H. Wright Mr. and Mrs. John G. Weiger Estate of Bernadette Wyrough Trust of Gertrude H. Weiler Ofer J. Yardeni Mrs. John L. Weinberg Mary and Bob Yellowlees

80. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER ADMINISTRATIVE BOARD

EXECUTIVE COMMITTEE

LAVINIA BRANCA SNYDER MRS. MICHAEL CARR ALEXIA HAMM RYAN MELANIE HOLLAND President Vice President Vice President Vice President

MRS. SCOTT C. JOHNSTON VICTORIA GREENLEAF MRS. THOMAS V. LEEDS Treasurer KEMPNER Past President Assistant Treasurer

MRS. LOUIS ROSE MRS. HILARY DICK Secretary Assistant Secretary

MEMBERS-AT-LARGE

Kate Allen Ruth G. Fleischmann Kamie Lightburn Mrs. Stephen C. Sherrill Muffie Potter Aston Mrs. Lars Forsberg Stephanie Loeffler Mrs. Sean P. Smith Mrs. James Halsey Bell Elizabeth Kirby Fuller Mrs. Roman Martinez IV Mrs. Paul Soros Mrs. Alan J. Blinken Mrs. Robert M. Gardiner Mrs. S. Christopher Meigher III Amanda Taylor Tory Burch Mrs. Mark V. Giordano Mrs. Richard A. Miller Mrs. Andrew S. Thomas Mrs. Bryan J. Carey Mrs. Thomas S. Glover Mrs. George F. Moss Maria von Bothmer Villalba Mrs. Kevin C. Coleman Eugenie Niven Goodman Joyce L. Moss Victoria Vought Mrs. Peter G. Cordeiro* Mrs. Peter S. Gregory Mrs. Timothy P. O’Hara Naomi Waletzky Mrs. Archibald Cox, Jr. Mrs. Roger P. Griswold, Jr. Jennifer Gaffney Oken Mrs. Martha Webster Jennifer Creel Shoshanna Gruss Mrs. Gunnar S Overstrom, III Eleanor Ylvisaker* Mrs. Michael J. A. Darling Leslie Heaney Marcie Pantzer Mrs. Thomas E. Zacharias Mrs. Marvin H. Davidson Shabnam Henry* Mrs. Richard T. Perkin Mrs. Caryn Zucker Webb Egerton Robyn Lane Joseph Mrs. Bambi Putnam Mrs. Christopher Errico Mrs. Michael Kennedy Shafi Roepers Gretchen Gunlocke Fenton* Martha O’Brien Lamphere Mrs. Paul C. Schorr IV

SUSTAINING BOARD

Courtney Arnot Mrs. Thomas J. Fahey, Jr. Mrs. Minot K. Milliken Leith Rutherfurd Talamo Mrs. Andres Bausili Mrs. Thomas M. Fitzgerald III Mrs. Charles H. Mott Mrs. Michael L. Tarnopol Mrs. Andrew M. Blum Mrs. Roberto de Guardiola Nancy Coffey Nagler Alexis Robinson Waller Dianne G. Crary Mrs. John S. Hilson Mrs. Samuel F. Pryor IV Mrs. Douglas A. Warner III Mrs. James F. Curtis III Mrs. Ann F. Jeffery Mrs. Benjamin M. Rosen Mrs. James H. Dean Suzie Kovner Evelyn Angevine Silla Antonia Paepcke DuBrul Mrs. Brian A. McCarthy Mrs. Richard J. Sterne

PRESIDENT’S COUNCIL

Mrs. Rand V. Araskog Nina Garcia Conrod Julie Geier Mrs. Donald B. Marron D. Dixon Boardman Mrs. Charles A. Dana, Jr. Mrs. Richard S. LeFrak Linda Gosden Robinson

PAST PRESIDENTS

Mrs. Coleman P. Burke Mrs. Bruce A. Gimbel Mrs. Arie L. Kopelman Dr. Annette U. Rickel Mrs. Edwin M. Burke Martha Vietor Glass Mrs. Derek L. Limbocker Mrs. Bijan Safai Mrs. William M. Carson Alison Barr Howard Jean Remmel Little Mrs. Walter B. Delafield Mrs. Peter D. Jones Mrs. M. Anthony May Mrs. Charles H. Dyson Mrs. Kerryn King Mrs. Frank A. Metz, Jr.

FOUNDER

Mrs. Edward C. Delafield

*indicates new member 81. INNOVATION

THE SOCIETY OF MEMORIAL SLOAN KETTERING CANCER CENTER

SUPPORTING RESEARCH role as a catalyst for recognizing globally important The Society of Memorial Sloan Kettering’s Special contributions to the field of pediatric oncology,” said Projects grants fund innovative research at the Sloan Lavinia Branca Snyder, President of The Society. Kettering Institute that is often too nascent to receive support from conventional sources. This year, the SUPPORTING PATIENT CARE grants were awarded to five scientists doing research Some of the most cherished traditions and events in nanotechnology, immunology, and molecular and at MSK — including the festive holiday parties held developmental biology. throughout the year, complete with overflowing gift bags for patients — are sponsored by The Society. This year Each spring, The Society also awards research grants was no different, with more than 200 of our youngest that specifically focus on providing crucial funding patients and their families and friends at Pediatric Prom to MSK’s promising young investigators. In 2016, in May 2016. the grants were awarded to nine projects, including a study involving patient-derived organoid models; The Society also bid a fond farewell to The Society a project to enhance end-of-life care; and a study Boutique (formerly The Society Thrift Shop) in developing and evaluating a fingerprinting tool to December. The much-beloved shop, founded in 1951, search for a common bacterium. raised millions of dollars in support of MSK and served as a neighborhood extension of the institution, drawing The Society’s Associates Initiative focused on genomic patrons from all over the city. profiling for pediatric cancer patients. Funds raised went to support crucial research at MSK into how certain gene SUPPORTING EDUCATION mutations lead to the development of cancers in children, The Society’s annual Health Education Seminar with the goal of creating more effective, personalized (HES) provides public education on the prevention, treatments for these young patients. early detection, and treatment of cancer. The 2016 HES topic focused on a vital aspect of the cancer care The Center for Hematologic Malignancies — created team: caregivers. The lecture included discussions on in 2016 to allow MSK investigators to continue to postoperative care and the psychology of caregiving as produce remarkable advances in our understanding of well as a talk from Kate Niehaus, a former MSK patient blood cancers — was the focus of the 2016-17 Society and long-time patient advisor who is Chair of MSK’s Campaign. Funds raised will directly support research Patient and Family Advisory Council for Quality. within the center and in the lab of physician-scientist Ross Levine. For many of the postdoctoral students in MSK’s research labs, the challenges of the job coincide with the demands To commemorate its 70th anniversary, The Society of family life. To help offer some stability, The Society announced the establishment of The Society of has established a merit-based prize specifically for young Memorial Sloan Kettering Prize, which will be awarded families to assist with childcare expenses. The Society annually to recognize important contributions to the Scholars Prize honors MSK’s most talented postdocs field of pediatric oncology. The inaugural recipient of the who are also parents to children under the age of four. award, former Chair of the Pediatrics Service Richard O’Reilly, stepped down in 2016. “As we look to the future with optimism, we are thrilled to aid MSK in its leading

82. MEMORIAL 2016 SLOAN KETTERING ANNUAL CANCER CENTER REPORT

COMPASSION, GENEROSITY OF SPIRIT, AND FORWARD THINKING HAS BEEN AT THE CORE OF THE SOCIETY OF MSK’S MANY-FACETED CONTRIBUTIONS FOR 70 YEARS.”

– DOUGLAS A. WARNER III CHAIR, BOARDS OF OVERSEERS AND MANAGERS 1

2

1. F rom left: Joan Massagué, Lavinia Branca Snyder, Richard O’Reilly, Nina Pickett, Craig Thompson, and Paul Meyers at the 2016 Spring Ball, at which Dr. O’Reilly was honored with the inaugural Society Prize in Pediatric Oncology. 2. Recipients of The Society’s Research Grants with Society President Lavinia Branca Snyder, fifth from right, and MSK Physician-in-Chief José Baselga, fourth from right. 3. A pediatric patient enjoying the annual pediatric prom. 3 4 4. From left: Kate Niehaus, Anna Kennedy Safir, Kent Sepkowitz, Eleanora Kennedy, Larissa Temple, Allison Applebaum, and Society President Lavinia Branca Snyder at the Health Education Seminar in April 2016.

83. INNOVATION

PRODUCED BY The Department of Communications Avice A. Meehan Memorial Sloan Kettering Cancer Center Senior Vice President and Chief Communications Officer 1275 York Avenue New York, NY 10065 Ami Schmitz Vice President, Editorial and Content Strategy t 212.639.3573 f 212.639.3576 MANAGING EDITOR PHOTOGRAPHY Jennifer Castoro Ian Spanier Photography

CREATIVE DIRECTOR ADDITIONAL PHOTOGRAPHY Randi Press Rick DeWitt Kreg Holt WRITERS Ethan Kavet Jennifer Castoro Karsten Moran Julie Grisham Michael Prince Matthew Tontonoz Matthew Septimus

PRODUCTION COORDINATOR DESIGN Emily Kastl Ideas On Purpose, New York www.ideasonpurpose.com CONTRIBUTORS Quasona Cobb PRINTING Kristin Glick Allied Printing Services Larissa Regala James Stallard © Copyright 2017 Memorial Sloan Kettering Cancer Center